(Mark
One)
|
|
[X]
|
ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
For
the fiscal year ended December 31,
2007
|
|
OR
|
|
[ ]
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
For
the transition period from ______________ to
______________
|
Commission
file number 1-12626
|
EASTMAN
CHEMICAL COMPANY
|
(Exact
name of registrant as specified in its
charter)
|
Delaware
|
62-1539359
|
|
(State
or other jurisdiction of
|
(I.R.S.
Employer
|
|
incorporation
or organization)
|
Identification
no.)
|
|
200
South Wilcox Drive
|
||
Kingsport,
Tennessee
|
37662
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
|
Registrant’s
telephone number, including area code: (423)
229-2000
|
Securities
registered pursuant to Section 12(b) of the Act:
|
||
Title of each class
|
Name of each exchange on which
registered
|
|
Common
Stock, par value $0.01 per share
|
New
York Stock Exchange
|
Securities
registered pursuant to Section 12(g) of the Act: None
|
Yes
|
No
|
|
Indicate
by check mark if the registrant is a well-known seasoned issuer, as
defined in Rule 405 of the Securities Act.
|
[X]
|
|
Yes
|
No
|
|
Indicate
by check mark if the registrant is not required to file reports pursuant
to Section 13 or 15(d) of the Act.
|
[X]
|
|
Yes
|
No
|
|
Indicate
by check mark whether the registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
|
[X]
|
|
Yes
|
No
|
|
Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of
Regulation S-K is not contained herein, and will not be contained, to the
best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K.
|
[X]
|
|
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company. See definition of "large accelerated filer,"
"accelerated filer" and "smaller reporting company" in Rule 12b-2 of the
Exchange Act.
Large
accelerated filer
[X]
Accelerated filer [ ]
Non-accelerated
filer
[ ] Smaller
reporting company [ ]
(Do
not check if a smaller reporting company)
|
||
Yes
|
No
|
|
Indicate
by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Act).
|
[X]
|
ITEM
|
PAGE
|
1.
|
5
|
||
1A.
|
22
|
||
1B.
|
23
|
||
2.
|
25
|
||
3.
|
26
|
||
4.
|
27
|
||
5.
|
28
|
||
6.
|
30
|
||
7.
|
32
|
||
7A.
|
75
|
||
8.
|
76
|
||
9.
|
130
|
||
9A.
|
130
|
||
9B.
|
130
|
||
10.
|
131
|
||
11.
|
131
|
||
12.
|
131
|
||
13.
|
132
|
||
14.
|
132
|
||
134
|
·
|
In
the CASPI segment, Eastman has completed a 25 percent expansion of its
hydrogenated hydrocarbon resins manufacturing capacity in Middelburg, the
Netherlands and has begun an additional 30 percent expansion which is
expected to be complete in early
2009.
|
·
|
In
the Fibers segment, the Company is expanding its acetate tow plant in
Workington, England, which will serve existing customers in Western Europe
and the growing demand in Eastern Europe. This expansion is
expected to be complete in the second half of
2008.
|
·
|
In
the SP segment, in 2007, Eastman commercialized new high-temperature
copolyester products, based on Eastman TritanTM
copolyester. The segment also had continued sales revenue
growth from cellulosic and copolyester products sold in the liquid crystal
displays market.
|
·
|
The
PCI segment has been restructured to improve long term profitability.
Eastman divested its Batesville, Arkansas manufacturing facility and
related assets and its specialty organic chemicals product lines in 2006
and is implementing a staged phase-out of its three older cracking units
in Longview, Texas. Eastman shut down the first of these
cracking units in fourth quarter
2007.
|
·
|
The
Performance Polymers segment is being restructured and the Company expects
substantially to improve the segment's profitability, in part enabled by
IntegRexTM
technology. In 2007, the Company began transforming the
Columbia, South Carolina polyethylene terephthalate ("PET") facility
through a planned shutdown of higher cost PET assets; divested its PET
manufacturing facilities in San Roque, Spain; Cosoleacaque, Mexico and
Zarate, Argentina; and entered into definitive agreements to sell its PET
polymers and purified terephthalic acid ("PTA") facility in the
Netherlands and the PET facility in the United Kingdom and related
businesses. Eastman divested its polyethylene ("PE")
business and related assets in
2006.
|
·
|
In
the acetyl stream, the Company begins with high sulfur coal which is then
gasified in its coal gasification facility. The resulting
synthesis gas is converted into a number of chemicals including methanol,
methyl acetate, acetic acid, and acetic anhydride. These
chemicals are used in products throughout the Company including acetate
tow, acetate yarn, and cellulose esters. The Company's ability
to use coal is a competitive advantage in both raw materials and
energy. Therefore, the Company is pursuing opportunities
further to leverage its coal-based process know-how in a corporate
initiative referred to as "chemicals from coal". Expanding the
products derived from industrial gasification-based raw materials rather
than natural gas and crude oil are expected to enable Eastman to
achieve lower, more stable costs.
|
·
|
In
the polyester stream, the Company begins with purchased paraxylene and
produces PTA for PET and copolyesters and dimethyl terephthalate ("DMT")
for copolyesters. PTA or DMT is then reacted with ethylene
glycol, which the Company both makes and purchases, along with other raw
materials (some of which the Company makes and are proprietary) to produce
PET and copolyesters. This backward integration of its
polyester manufacturing is a competitive advantage, giving Eastman
a low cost position, as well as surety of intermediate
supply. In addition, Eastman adds specialty monomers for
copolyesters to provide clear, tough, chemically resistant product
characteristics. As a result, the Company's copolyesters can
compete with materials such as polycarbonate and
acrylic.
|
·
|
In
the olefins stream, the Company begins primarily with propane and ethane,
which are then cracked at its facility in Longview, Texas into propylene
and ethylene. The Company also purchases propylene for use at
its Longview facility and its facilities outside the
U.S. The propylene is used in oxo derivative products, while
the ethylene is used in oxo derivatives, acetaldehyde and ethylene glycol
production and also sold. Petrochemical business cycles are
influenced by periods of over- and under-capacity. Capacity
additions to steam cracker units around the world, combined with demand
for light olefins, determine the operating rate and thus profitability of
producing olefins. Historically, periodic additions of
large blocks of capacity have caused profit margins of light olefins to be
very volatile, resulting in "ethylene" or "olefins"
cycles.
|
SITE
|
ACETYL
STREAM
|
POLYESTER
STREAM
|
OLEFINS
STREAM
|
Kingsport,
Tennessee
|
X
|
X
|
X
|
Longview,
Texas
|
X
|
X
|
|
Columbia,
South Carolina
|
X
|
||
Rotterdam,
the Netherlands *
|
X
|
||
Workington,
England *
|
X
|
X
|
|
Kuantan,
Malaysia
|
X
|
||
Singapore
|
X
|
SEGMENT
|
ACETYL
STREAM
|
POLYESTER
STREAM
|
OLEFINS
STREAM
|
KEY
PRODUCTS, MARKETS AND
END
USES
|
CASPI
|
X
|
X
|
Adhesives
ingredients (tape, label, nonwovens), paint and coatings (architectural,
automotive, industrial, and original equipment manufacturing
("OEM"))
|
|
Fibers
|
X
|
Acetate
fibers for filter products and textiles
|
||
PCI
|
X
|
X
|
X
|
Intermediate
chemicals for agrochemical, automotive, beverages, nutrition,
pharmaceuticals, coatings, medical devices, toys, photographic and
imaging, household products, polymers, textiles, and consumer and
industrial products and uses
|
Performance
Polymers
|
X
|
X
|
PET
for beverage and food packaging, custom-care and cosmetic packaging,
health care and pharmaceutical uses, household products, and industrial
packaging applications
|
|
SP
|
X
|
X
|
X
|
Copolyesters
and cellulosics for appliances, store fixtures and displays, building and
construction, electronic packaging, medical devices and packaging, graphic
arts, general purpose packaging, personal care and cosmetics, food and
beverage packaging, performance films, tape and labels, fibers/nonwovens,
photographic and optical films, and liquid crystal displays
|
·
|
Overview
|
·
|
Products
|
Ø
|
Coatings
Additives, Coalescents, and
Solvents
|
Ø
|
Adhesives
Raw Materials
|
·
|
Strategy
and Innovation
|
·
|
Customers
and Markets
|
·
|
Competition
|
·
|
Overview
|
·
|
Products
|
Ø
|
Acetate
Tow
|
|
Ø
|
Acetyl Chemical
Products
|
·
|
Strategy and
Innovation
|
|
Ø
|
Growth
|
|
Ø
|
Continue to Capitalize on
Fibers Technology Expertise
|
Ø
|
Maintain
Cost-Effective Operations and Consistent Cash Flows and
Earnings
|
Ø
|
Research
and Development
|
·
|
Customers and
Markets
|
·
|
Competition
|
·
|
Overview
|
·
|
Products
|
·
|
Strategy
and Innovation
|
·
|
Customers
and Markets
|
·
|
Competition
|
·
|
Overview
|
·
|
Products
|
Ø
|
PET
|
·
|
Strategy
and Innovation
|
Ø
|
Growth
|
Ø
|
Innovation
|
Ø
|
Research
and Development
|
·
|
Lowering
manufacturing costs through process technology innovations and process
improvement efforts;
|
·
|
Developing
new products and services in PET polymers that both meet customers'
fitness for use requirements and are protective of the environment through
applications research and customer feedback;
and
|
·
|
Enhancing
product quality by improvements in manufacturing technology and
processes.
|
·
|
Customers
and Markets
|
·
|
Competition
|
·
|
Overview
|
·
|
Products
|
Ø
|
Specialty
Copolyesters
|
Ø
|
Cellulosic
Plastics
|
·
|
Strategy
and Innovation
|
·
|
Customers
and Markets
|
·
|
Competition
|
Segment using manufacturing
facility
|
|||||
Location
|
CASPI
|
PCI
|
SP
|
Performance
Polymers
|
Fibers
|
USA
|
|||||
Jefferson,
Pennsylvania
|
x
|
||||
Columbia,
South Carolina
|
x
|
x
|
|||
Kingsport,
Tennessee
|
x
|
x
|
x
|
x
|
x
|
Longview,
Texas
|
x
|
x
|
x
|
||
Franklin,
Virginia(1)
|
x
|
||||
Europe
|
|||||
Workington,
England (2)
|
x
|
x
|
|||
Middelburg,
the Netherlands
|
x
|
||||
Rotterdam,
the Netherlands (1)
(2)
|
x
|
||||
Llangefni,
Wales
|
x
|
||||
Asia
Pacific
|
|||||
Kuantan,
Malaysia (1)
|
x
|
||||
Jurong
Island, Singapore (1)
|
x
|
x
|
|||
Zibo
City, China(3)
|
x
|
x
|
|||
Latin
America
|
|||||
Uruapan,
Mexico
|
x
|
|
(1)
|
Indicates
a location that Eastman leases from a third
party.
|
(2)
|
Rotterdam,
the Netherlands and the Performance Polymers portion of the Workington,
England facility are included in assets held for sale at December 31,
2007.
|
|
(3)
|
Eastman
holds a 51 percent share in the joint venture Qilu Eastman Specialty
Chemical Ltd.
|
High
|
Low
|
Cash
Dividends Declared
|
|||||
2007
|
First
Quarter
|
$
|
64.77
|
$
|
57.54
|
$
|
0.44
|
Second
Quarter
|
69.77
|
63.02
|
0.44
|
||||
Third
Quarter
|
72.44
|
61.55
|
0.44
|
||||
Fourth
Quarter
|
68.97
|
58.81
|
0.44
|
||||
2006
|
First
Quarter
|
$
|
53.83
|
$
|
47.30
|
$
|
0.44
|
Second
Quarter
|
58.15
|
50.00
|
0.44
|
||||
Third
Quarter
|
54.69
|
48.72
|
0.44
|
||||
Fourth
Quarter
|
61.29
|
53.62
|
0.44
|
Period
|
Total
Number
of
Shares
Purchased
(1)
|
Average
Price Paid Per Share
(2)
|
Total
Number of Shares Purchased as Part of Publicly Announced
Plans
or
Programs
(3)
|
Approximate
Dollar
Value
(in Millions) that May Yet Be Purchased Under the Plans or
Programs
(3)
|
|||
October
1- 31, 2007
|
3,405
|
$
|
68.00
|
0
|
$
|
700
|
|
November
1-30, 2007
|
768,200
|
60.89
|
768,200
|
653
|
|||
December
1-31, 2007
|
556,800
|
63.08
|
556,800
|
|
618
|
||
Total
|
1,328,405
|
61.83
|
1,325,000
|
(1)
|
Shares
purchased as part of the Company's repurchase plan and
shares surrendered to the Company by employees to satisfy individual tax
withholding obligations upon vesting of previously issued shares of
restricted common stock.
|
(2)
|
Average
price paid per share reflects the individual trade price of repurchases
under the authorized Company repurchase plan and the weighted average of
the closing price of Eastman common stock on the business days the shares
were surrendered by the employee stockholders to satisfy individual tax
withholding obligations.
|
(3)
|
In
October 2007, the Board of Directors authorized $700 million for
repurchase of the Company's outstanding common shares at such times, in
such amounts, and on such terms, as determined to be in the best interests
of the Company. As of December 31, 2007, a total of 1.3 million
shares have been repurchased under this authorization for a total amount
of $82 million. For
additional information, see Note 15, "Stockholders' Equity", to the
Company’s consolidated financial statements in Part II, Item 8 of this
2007 Annual Report on Form 10-K.
|
Summary
of Operating Data
|
Year Ended December 31, | |||||||||
(Dollars
in millions, except per share amounts)
|
2007
|
2006
|
2005
|
2004
|
2003
|
|||||
Sales
|
$
|
6,830
|
$
|
6,779
|
$
|
6,460
|
$
|
6,019
|
$
|
5,377
|
Operating
earnings (loss)
|
504
|
654
|
740
|
146
|
(275)
|
|||||
Earnings
(loss) from continuing operations
|
321
|
427
|
541
|
146
|
(276)
|
|||||
Earnings
(loss) from discontinued operations
|
(10)
|
(18)
|
16
|
24
|
3
|
|||||
Loss
from disposal of discontinued operations
|
(11)
|
--
|
--
|
--
|
--
|
|||||
Cumulative
effect of change in accounting principles, net
|
--
|
--
|
--
|
--
|
3
|
|||||
Net
earnings (loss)
|
$
|
300
|
$
|
409
|
$
|
557
|
$
|
170
|
$
|
(270)
|
Basic
earnings per share
|
||||||||||
Earnings
(loss) from continuing operations
|
$
|
3.89
|
$
|
5.20
|
$
|
6.70
|
$
|
1.88
|
$
|
(3.58)
|
Earnings
(loss) from discontinued operations
|
(0.26)
|
(0.22)
|
0.20
|
0.32
|
0.04
|
|||||
Cumulative
effect of change in accounting principles, net
|
--
|
--
|
--
|
--
|
0.04
|
|||||
Net
earnings (loss)
|
$
|
3.63
|
$
|
4.98
|
$
|
6.90
|
$
|
2.20
|
$
|
(3.50)
|
Diluted
earnings per share
|
||||||||||
Earnings
(loss) from continuing operations
|
$
|
3.84
|
$
|
5.12
|
$
|
6.61
|
$
|
1.86
|
$
|
(3.58)
|
Earnings
(loss) from discontinued operations
|
(0.26)
|
(0.21)
|
0.20
|
0.32
|
0.04
|
|||||
Cumulative
effect of change in accounting principles, net
|
--
|
--
|
--
|
--
|
0.04
|
|||||
Net
earnings (loss)
|
$
|
3.58
|
$
|
4.91
|
$
|
6.81
|
$
|
2.18
|
$
|
(3.50)
|
Statement
of Financial Position Data
|
||||||||||
Current
assets
|
$
|
2,293
|
$
|
2,422
|
$
|
1,924
|
$
|
1,768
|
$
|
2,010
|
Net
properties
|
2,846
|
3,069
|
3,162
|
3,192
|
3,419
|
|||||
Total
assets
|
6,009
|
6,132
|
5,773
|
5,839
|
6,244
|
|||||
Current
liabilities
|
1,122
|
1,059
|
1,051
|
1,099
|
1,477
|
|||||
Long-term
borrowings
|
1,535
|
1,589
|
1,621
|
2,061
|
2,089
|
|||||
Total
liabilities
|
3,927
|
4,103
|
4,161
|
4,655
|
5,201
|
|||||
Total
stockholders’ equity
|
2,082
|
2,029
|
1,612
|
1,184
|
1,043
|
|||||
Dividends
declared per share
|
1.76
|
1.76
|
1.76
|
1.76
|
1.76
|
MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
ITEM
|
Page
|
33
|
|
36
|
|
37
|
|
38
|
|
43
|
|
50
|
|
51
|
|
55
|
|
61
|
|
62
|
|
66
|
|
68
|
|
68
|
|
69
|
|
71
|
|
Change
in
Assumption
|
Impact
on
2008
Pre-tax U.S.
Benefits
Expense
|
Impact
on
December
31, 2007
Projected
Benefit Obligation for
U.S.
Pension Plan
|
Impact
on
December
31, 2007
Benefit
Obligation for
Other
U.S. Postretirement Plans
|
25
basis point
decrease
in discount
rate
|
+$5
Million
|
+$41
Million
|
+$20
Million
|
25
basis point
increase
in discount
rate
|
-$5
Million
|
-$39
Million
|
-$19
Million
|
25
basis point
decrease
in expected
return
on assets
|
+$3
Million
|
No
Impact
|
N/A
|
25
basis point
increase
in expected
return
on assets
|
-$3
Million
|
No
Impact
|
N/A
|
·
|
Company
sales and segment sales and results from continuing operations excluding
sales revenue and results from continuing operations from sales in Latin
America of PET products manufactured at the divested Mexico and Argentina
PET manufacturing sites;
|
·
|
Company
and segment sales excluding contract ethylene sales under a transition
agreement related to the PE product lines divested in
2006;
|
·
|
Company
sales and segment sales and results from continuing operations excluding
sales revenue and operating results from the product lines
divested in 2006; and
|
·
|
Company
and segment gross profit, operating earnings, and net earnings excluding
accelerated depreciation costs, asset impairments and restructuring
charges (gains), and other operating (income) loss,
net.
|
Volume
Effect
|
Price
Effect
|
Product
Mix
Effect
|
Exchange
Rate
Effect
|
|||||||||||
(Dollars
in millions)
|
2007
|
2006
|
Change
|
|||||||||||
Sales
|
$
|
6,830
|
$
|
6,779
|
1
%
|
(3)
%
|
3
%
|
--
%
|
1
%
|
|||||
Sales
- contract ethylene sales (1)
|
314
|
27
|
||||||||||||
Sales
– 2006 divested product lines (2)
|
--
|
811
|
||||||||||||
Sales
- sales from Mexico and Argentina PET manufacturing facilities (3)
|
413
|
440
|
||||||||||||
Sales
– excluding listed items
|
$
|
6,103
|
$
|
5,501
|
11
%
|
5
%
|
4
%
|
1
%
|
1
%
|
|||||
|
(1)
Included in 2007 and 2006 sales revenue are contract ethylene sales under
the transition supply agreement related to the divestiture of the PE
businesses.
|
|
(2)
Included in 2006 sales revenue are sales revenue from sales of products of
the divested product lines of the Company's Batesville, Arkansas
manufacturing facility and related assets in the PCI segment and of the
divested PE and EpoleneTM
polymer businesses and related assets of the Performance Polymers and
CASPI segments.
|
|
(3)
Included in 2007 and 2006 sales revenue are sales revenue from PET
manufacturing facilities and related businesses in Cosoleacaque, Mexico
and Zarate, Argentina divested in the fourth quarter
2007. These sales are not considered discontinued operations
due to continuing involvement in the Latin America region and raw material
sales to the divested facilities.
|
(Dollars
in millions)
|
2007
|
2006
|
Change
|
|||
Gross
Profit
|
$
|
1,192
|
$
|
1,265
|
(6)
%
|
|
As
a percentage of sales
|
17.5
%
|
18.7
%
|
||||
Accelerated
depreciation included in cost of goods sold
|
49
|
10
|
||||
Gross
Profit excluding accelerated depreciation costs
|
1,241
|
1,275
|
(3)
%
|
|||
As
a percentage of sales
|
18.2
%
|
18.8
%
|
(Dollars
in millions)
|
2007
|
2006
|
Change
|
|||
Selling,
General and Administrative Expenses ("SG&A")
|
$
|
420
|
$
|
423
|
(1)
%
|
|
Research
and Development Expenses ("R&D")
|
156
|
155
|
--
%
|
|||
$
|
576
|
$
|
578
|
--
%
|
||
As
a percentage of sales
|
8.4%
|
8.5%
|
2007
|
2006
|
Change
|
||||
(Dollars
in millions)
|
||||||
Operating
earnings
|
$
|
504
|
$
|
654
|
(23)
%
|
|
Accelerated
depreciation included in cost of goods sold
|
49
|
10
|
||||
Asset
impairments and restructuring charges, net
|
112
|
101
|
||||
Other
operating income, net
|
--
|
(68)
|
||||
Operating
earnings excluding accelerated depreciation costs, asset impairment and
restructuring charges, net, and other operating income,
net
|
$
|
665
|
$
|
697
|
(5)
%
|
(Dollars
in millions)
|
2007
|
2006
|
Change
|
|||
Gross
interest costs
|
$
|
113
|
$
|
109
|
||
Less:
capitalized interest
|
10
|
7
|
||||
Interest
expense
|
103
|
102
|
1
%
|
|||
Interest
income
|
41
|
25
|
||||
Interest
expense, net
|
$
|
62
|
$
|
77
|
(19)
%
|
(Dollars
in millions)
|
2007
|
2006
|
Change
|
|||
Other
income
|
$
|
(33)
|
$
|
(25)
|
$
|
(8)
|
Other
charges
|
5
|
8
|
(3)
|
|||
Other
(income) charges, net
|
$
|
(28)
|
$
|
(17)
|
$
|
(11)
|
(Dollars
in millions)
|
2007
|
2006
|
Change
|
|||
Provision
for income taxes
|
$
|
149
|
$
|
167
|
(11)
%
|
|
Effective
tax rate
|
32
%
|
28
%
|
Earnings
from Continuing Operations
|
||||
(Dollars
in millions)
|
2007
|
2006
|
||
Earnings
from continuing operations
|
$
|
321
|
$
|
427
|
Accelerated
depreciation included in cost of goods sold, net of tax
|
31
|
6
|
||
Asset
impairments and restructuring charges, net of tax
|
71
|
69
|
||
Other
operating income, net
|
--
|
(68)
|
||
Earnings
from continuing operations excluding accelerated depreciation costs, asset
impairments and restructuring charges, net of tax, and other operating
income, net
|
$
|
423
|
$
|
434
|
(Dollars
in millions)
|
2007
|
2006
|
||
Earnings
from continuing operations
|
$
|
321
|
$
|
427
|
Loss
from discontinued operations, net of tax
|
(10)
|
|
(18)
|
|
Loss
on disposal of discontinued operations, net of tax
|
(11)
|
--
|
||
Net
earnings
|
$
|
300
|
$
|
409
|
CASPI
Segment
|
|||||||||||||
Change
|
|||||||||||||
(Dollars
in millions)
|
2007
|
2006
|
$
|
%
|
|||||||||
Sales
|
$
|
1,451
|
$
|
1,421
|
$
|
30
|
2
%
|
||||||
Volume
effect
|
(68)
|
(5)
%
|
|||||||||||
Price
effect
|
48
|
3
%
|
|||||||||||
Product
mix effect
|
26
|
2
%
|
|||||||||||
Exchange
rate effect
|
24
|
2
%
|
|||||||||||
Operating
earnings
|
235
|
229
|
6
|
3
%
|
|||||||||
Asset
impairments and restructuring charges, net
|
(1)
|
13
|
(14)
|
||||||||||
Operating
earnings excluding asset impairments and restructuring charges,
net
|
234
|
242
|
(8)
|
(3)
%
|
Fibers
Segment
|
|||||||||||||
Change
|
|||||||||||||
(Dollars
in millions)
|
2007
|
2006
|
$
|
%
|
|||||||||
Sales
|
$
|
999
|
$
|
910
|
$
|
89
|
10
%
|
||||||
Volume
effect
|
25
|
3
%
|
|||||||||||
Price
effect
|
51
|
6
%
|
|||||||||||
Product
mix effect
|
9
|
1
%
|
|||||||||||
Exchange
rate effect
|
4
|
--
%
|
|||||||||||
Operating
earnings
|
238
|
226
|
12
|
5
%
|
|||||||||
Asset
impairments and restructuring charges, net
|
--
|
2
|
(2)
|
||||||||||
Operating
earnings excluding asset impairments and restructuring charges,
net
|
238
|
228
|
10
|
4
%
|
PCI
Segment
|
||||||||||
Change
|
||||||||||
(Dollars
in millions)
|
2007
|
2006
|
$
|
%
|
||||||
Sales
|
$
|
2,095
|
$
|
1,659
|
$
|
436
|
26
%
|
|||
Volume
effect
|
401
|
24
%
|
||||||||
Price
effect
|
74
|
4
%
|
||||||||
Product
mix effect
|
(49)
|
(3)
%
|
||||||||
Exchange
rate effect
|
10
|
1
%
|
||||||||
Sales
– contract ethylene sales (1)
|
314
|
27
|
287
|
|||||||
Sales
– divested product lines (2)
|
--
|
111
|
(111)
|
|||||||
Sales
– excluding listed items
|
1,781
|
1,521
|
260
|
17
%
|
||||||
Volume
effect
|
131
|
9
%
|
||||||||
Price
effect
|
98
|
6
%
|
||||||||
Product
mix effect
|
22
|
1
%
|
||||||||
Exchange
rate effect
|
9
|
1
%
|
||||||||
Operating
earnings
|
220
|
132
|
88
|
67
%
|
||||||
Operating
earnings (loss) – divested product lines (2)(3)
|
--
|
(15)
|
15
|
100
%
|
||||||
Operating
earnings – excluding divested product lines (3)
|
220
|
147
|
73
|
50
%
|
||||||
Operating
earnings excluding certain items (4)
|
238
|
161
|
77
|
48
%
|
||||||
Operating
earnings excluding certain items (4)
– divested product lines (2)(3)
|
--
|
3
|
(3)
|
(100)%
|
||||||
Operating
earnings excluding certain items (4)
– excluding divested product lines (3)
|
238
|
158
|
80
|
51
%
|
|
(1)
Sales revenue for 2007 and 2006 included contract ethylene sales under the
transition supply agreement related to the divestiture of the PE
businesses.
|
|
(2)
Sales revenue and operating results for 2006 included sales revenue from
sales of products of the divested product lines of the Company's
Batesville, Arkansas manufacturing facility and related assets and
specialty organic chemicals product
lines.
|
|
(3) Includes
allocated costs consistent with the Company’s historical practices, some
of which may remain and could be reallocated to the remainder of the
segment and other segments.
|
|
(4)
Items are accelerated depreciation costs, asset impairments and
restructuring charges (gains) and other operating
charges. Accelerated depreciation costs and asset impairments
and restructuring gains for 2007 were $19 million and $1 million,
respectively. Accelerated depreciation costs, asset impairments
and restructuring charges, and other operating charges for 2006 were $2
million, $20 million, and $7 million, respectively. The accelerated
depreciation costs are related to the continuation of the planned staged
phase-out of older cracking units at the Company's Longview, Texas
facility. Asset impairments and restructuring charges were
primarily related to the divestiture of the PCI segment's Batesville,
Arkansas manufacturing facility and related assets and specialty organic
chemicals product lines completed in the fourth quarter 2006 and to
severance costs related to a voluntary reduction in force in
2006. The other operating charges resulted from the Batesville,
Arkansas divestiture.
|
Change
|
||||||||||
(Dollars
in millions)
|
2007
|
2006
|
$
|
%
|
||||||
Sales
|
$
|
1,413
|
$
|
1,971
|
$
|
(558)
|
(28)
%
|
|||
Volume
effect
|
(557)
|
(28)
%
|
||||||||
Price
effect
|
(5)
|
--
%
|
||||||||
Product
mix effect
|
4
|
--
%
|
||||||||
Exchange
rate effect
|
--
|
--
%
|
||||||||
Sales
– divested PE product lines (1)
|
--
|
635
|
(635)
|
(100)%
|
||||||
Sales
from Mexico and Argentina PET manufacturing facilities (2)
|
413
|
440
|
(27)
|
(6)%
|
||||||
Sales
– U.S. PET manufacturing facilities
|
1,000
|
896
|
104
|
12%
|
||||||
Volume
effect
|
115
|
13%
|
||||||||
Price
effect
|
(15)
|
(1)%
|
||||||||
Product
mix effect
|
4
|
--
%
|
||||||||
Exchange
rate effect
|
--
|
--
%
|
||||||||
Operating
earnings (loss) (3)
|
(207)
|
68
|
(275)
|
>(100)
%
|
||||||
Operating
earnings - divested PE product lines (1)(4)
|
--
|
136
|
(136)
|
(100)
%
|
||||||
Operating
loss - from sales from Mexico and Argentina PET
manufacturing facilities (2)(4)
|
(127)
|
(12)
|
(115)
|
>(100)
%
|
||||||
Operating
loss - U.S. PET manufacturing facilities (3)(4)
|
(80)
|
(56)
|
(24)
|
(43)
%
|
(1)
|
PE
product lines of the PE businesses and related assets located at the
Longview, Texas site which were sold in fourth quarter
2006.
|
(2)
|
Sales
revenue and operating results for 2007 and 2006 include sales revenue from
PET manufacturing facilities and related businesses in Cosoleacaque,
Mexico and Zarate, Argentina divested in fourth quarter
2007. These sales are not presented as discontinued
operations due to the Performance Polymers segment's continuing
involvement in the Latin American region and raw material sales to the
divested facilities.
|
(3)
|
Includes
allocated costs not included in discontinued operations, some of which may
remain and could be reallocated to the remainder of the segment and other
segments.
|
(4)
|
Includes
allocated costs consistent with the Company's historical practices, some
of which may remain and could be reallocated to the remainder of the
segment and other segments.
|
Performance
Polymers Segment
|
||||||||
Change
|
||||||||
(Dollars
in millions)
|
2007
|
2006
|
$
|
%
|
||||
Operating
earnings (loss) excluding certain items (1)(2)
|
$
|
(65)
|
$
|
46
|
$ |
(111)
|
>(100)
%
|
|
Operating
earnings excluding certain items (3)
- divested PE product line (4)
|
--
|
61
|
(61)
|
>(100)
%
|
||||
Operating
loss excluding certain items (5)
- from sales from Mexico and Argentina PET manufacturing facilities
(6)
|
(12)
|
(12)
|
--
|
--
%
|
||||
Operating
loss excluding certain items (7) -
U.S. PET manufacturing facilities (1)
|
(53)
|
(3)
|
(50)
|
>(100)
%
|
(1)
|
Includes
allocated costs not included in discontinued operations, some of which may
remain and could be reallocated to the remainder of the segment and other
segments.
|
(2)
|
Items
are accelerated depreciation costs, asset impairments and restructuring
charges, net and other operating income. In 2007, asset
impairments and restructuring charges of $113 million primarily related to
the Mexico and Argentina PET manufacturing facilities sale. Accelerated
depreciation costs of $29 million resulted from restructuring actions
associated with higher cost PET polymer assets in Columbia, South
Carolina. In 2006, asset impairments and restructuring charges
of $46 million were primarily related to the shutdown of a research and
development Kingsport, Tennessee pilot plant, discontinued production of
CHDM modified polymers in San Roque, Spain and severance costs from a
reduction in force in the U.S. and Spain. CHDM, an internal
intermediate product primarily used in copolyester and PET production, was
discontinued in San Roque, Spain to gain operational efficiencies at other
facilities. Accelerated depreciation of $7 million in 2006
related to the restructuring decisions and actions for higher cost PET
polymer intermediates assets in Columbia. Other operating income was $75
million in 2006 from the divestiture of the PE businesses and
assets.
|
(3)
|
Items
are other operating income from the sale of the PE businesses and related
assets located at the Longview, Texas site which were sold in fourth
quarter 2006, and which were $75 million in
2006.
|
(4)
|
PE
product lines of the PE businesses and related assets located at the
Longview, Texas site which were sold in fourth quarter
2006. Includes allocated costs consistent with the Company's
historical practices, some of which may remain and could be reallocated to
the remainder of the segment and other
segments.
|
(5)
|
Items
are asset impairments and restructuring charges (gains) relating to the
Mexico and Argentina PET manufacturing facilities, and were $115 million
in 2007.
|
(6)
|
Sales
revenue and operating results for 2007 and 2006 include sales revenue from
PET manufacturing facilities and related businesses in Mexico and
Argentina divested in fourth quarter 2007. These sales are not
presented as discontinued operations due to the Performance Polymers
segment's continuing involvement in the Latin American region and raw
material sales to the divested facilities. Includes allocated
costs consistent with the Company's historical practices, some of which
may remain and could be reallocated to the remainder of the segment and
other segments.
|
(7)
|
Items
are accelerated depreciation costs and asset impairments and restructuring
charges (gains) related to the U.S. PET manufacturing
facilities. Asset impairments and restructuring charges (gains)
were $(2) million and $46 million in 2007 and 2006,
respectively. Accelerated depreciation costs were $29 million
and $7 million in 2007 and 2006,
respectively.
|
SP
Segment
|
|||||||||
Change
|
|||||||||
(Dollars
in millions)
|
2007
|
2006
|
$
|
%
|
|||||
Sales
|
$
|
872
|
$
|
818
|
$
|
54
|
6
%
|
||
Volume
effect
|
10
|
1
%
|
|||||||
Price
effect
|
23
|
3
%
|
|||||||
Product
mix effect
|
10
|
1
%
|
|||||||
Exchange
rate effect
|
11
|
1
%
|
|||||||
Operating
earnings
|
65
|
46
|
19
|
41
%
|
|||||
Accelerated
depreciation included in cost of goods sold
|
1
|
1
|
--
|
||||||
Asset
impairments and restructuring charges, net
|
1
|
16
|
(15)
|
||||||
Operating
earnings excluding accelerated depreciation costs and asset impairments
and restructuring charges, net
|
67
|
63
|
4
|
6
%
|
(Dollars
in millions)
|
2007
|
2006
|
Change
|
Volume
Effect
|
Price
Effect
|
Product
Mix
Effect
|
Exchange
Rate
Effect
|
|||||||
United
States and Canada
|
$
|
4,043
|
$
|
4,221
|
(4)
%
|
(4)
%
|
2
%
|
(2)
%
|
--
%
|
|||||
Europe,
Middle East, and Africa
|
932
|
816
|
14
%
|
3
%
|
3
%
|
2
%
|
6
%
|
|||||||
Asia
Pacific
|
1,103
|
941
|
17
%
|
3
%
|
8
%
|
6
%
|
--
%
|
|||||||
Latin
America
|
752
|
801
|
(6)
%
|
(8)
%
|
2
%
|
--
%
|
--
%
|
|||||||
$
|
6,830
|
$
|
6,779
|
1
%
|
(3)
%
|
3
%
|
--
%
|
1
%
|
Volume
Effect
|
Price
Effect
|
Product
Mix
Effect
|
Exchange
Rate
Effect
|
|||||||||||
(Dollars
in millions)
|
2006
|
2005
|
Change
|
|||||||||||
Sales
|
$
|
6,779
|
$
|
6,460
|
5
%
|
1
%
|
5
%
|
(1)
%
|
--
%
|
|||||
Sales
– 2006 divested product lines (1)
|
811
|
786
|
||||||||||||
Sales
- sales from Mexico and
Argentina PET manufacturing facilities (2)
|
440
|
427
|
||||||||||||
Sales
– excluding listed items
|
$
|
5,528
|
$
|
5,247
|
5
%
|
--
%
|
6
%
|
(1)
%
|
--
%
|
|||||
(1)
|
Included in 2006 and 2005
sales revenue are sales revenue from sales of products of the divested
product lines of the Company's Batesville, Arkansas manufacturing facility
and related assets in the PCI segment and of the divested PE and
EpoleneTM
polymer businesses and related assets of the Performance Polymers and
CASPI segments.
|
(2)
|
Included in 2006 and 2005 sales
revenue are sales revenue from PET manufacturing facilities and related
businesses in Cosoleacaque, Mexico and Zarate, Argentina divested in
fourth quarter 2007. These sales are not considered
discontinued operations due to continuing involvement in the Latin America
region and raw material sales to the divested
facilities.
|
(Dollars
in millions)
|
2006
|
2005
|
Change
|
|||
Gross
Profit
|
$
|
1,265
|
$
|
1,360
|
(7)
%
|
|
As
a percentage of sales
|
18.7
%
|
21.1
%
|
||||
Accelerated
depreciation included in cost of goods sold
|
10
|
--
|
||||
Gross
Profit excluding accelerated depreciation costs
|
1,275
|
1,360
|
(6)
%
|
|||
As
a percentage of sales
|
18.8
%
|
21.1
%
|
(Dollars
in millions)
|
2006
|
2005
|
Change
|
|||
SG&A
Expenses
|
$
|
423
|
$
|
439
|
(4)
%
|
|
R&D
Expenses
|
155
|
150
|
(3)
%
|
|||
$
|
578
|
$
|
589
|
(2)
%
|
||
As
a percentage of sales
|
8.5%
|
9.1%
|
Operating
Earnings
|
||||||
2006
|
2005
|
Change
|
||||
(Dollars
in millions)
|
||||||
Operating
earnings
|
$
|
654
|
$
|
740
|
(12)
%
|
|
Accelerated
depreciation included in cost of goods sold
|
10
|
--
|
||||
Asset
impairments and restructuring charges, net
|
101
|
33
|
||||
Other
operating income, net
|
(68)
|
(2)
|
||||
Operating
earnings excluding accelerated depreciation costs, asset impairment and
restructuring charges, net, and other operating income,
net
|
$
|
697
|
$
|
771
|
(10)
%
|
(Dollars
in millions)
|
2006
|
2005
|
Change
|
|||
Gross
interest costs
|
$
|
109
|
$
|
118
|
||
Less:
capitalized interest
|
7
|
5
|
||||
Interest
expense
|
102
|
113
|
(10)
%
|
|||
Interest
income
|
25
|
13
|
||||
Interest
expense, net
|
$
|
77
|
$
|
100
|
(23)
%
|
(Dollars
in millions)
|
2006
|
2005
|
Change
|
|||
Other
income
|
$
|
(25)
|
$
|
(8)
|
$
|
(17)
|
Other
charges
|
8
|
12
|
(4)
|
|||
Other
(income) charges, net
|
$
|
(17)
|
$
|
4
|
$
|
(21)
|
(Dollars
in millions)
|
2006
|
2005
|
Change
|
|||
Provision
for income taxes
|
$
|
167
|
$
|
222
|
(25)
%
|
|
Effective
tax rate
|
28
%
|
29
%
|
Earnings
from Continuing Operations
|
||||
(Dollars
in millions)
|
2006
|
2005
|
||
Earnings
from continuing operations
|
$
|
427
|
$
|
541
|
Accelerated
depreciation included in cost of goods sold, net of tax
|
6
|
--
|
||
Asset
impairments and restructuring charges, net of tax
|
69
|
23
|
||
Other
operating income
|
(68)
|
(1)
|
||
Gain
on sale of investment in Genencor
|
--
|
(111)
|
||
Early
extinguishment of debt costs
|
--
|
28
|
||
Net
deferred tax benefit related to sale of certain businesses, product lines,
and assets in the CASPI segment
|
--
|
(12)
|
||
Earnings
from continuing operations excluding listed items
|
$
|
434
|
$
|
468
|
(Dollars
in millions)
|
2006
|
2005
|
||
Earnings
from continuing operations
|
$
|
427
|
$
|
541
|
Earnings
(loss) from discontinued operations, net of tax
|
(18)
|
16
|
||
Net
earnings
|
$
|
409
|
$
|
557
|
CASPI
Segment
|
|||||||||||||
Change
|
|||||||||||||
(Dollars
in millions)
|
2006
|
2005
|
$
|
%
|
|||||||||
Sales
|
$
|
1,421
|
$
|
1,299
|
$
|
122
|
9
%
|
||||||
Volume
effect
|
6
|
--
%
|
|||||||||||
Price
effect
|
115
|
9
%
|
|||||||||||
Product
mix effect
|
4
|
--
%
|
|||||||||||
Exchange
rate effect
|
(3)
|
--
%
|
|||||||||||
Operating
earnings
|
229
|
228
|
1
|
--
%
|
|||||||||
Asset
impairments and restructuring charges, net
|
13
|
4
|
9
|
||||||||||
Operating
earnings excluding asset impairments and restructuring charges,
net
|
242
|
232
|
10
|
4
%
|
Fibers
Segment
|
|||||||||||||
Change
|
|||||||||||||
(Dollars
in millions)
|
2006
|
2005
|
$
|
%
|
|||||||||
Sales
|
$
|
910
|
$
|
869
|
$
|
41
|
5
%
|
||||||
Volume
effect
|
17
|
2
%
|
|||||||||||
Price
effect
|
55
|
6
%
|
|||||||||||
Product
mix effect
|
(31)
|
(3)
%
|
|||||||||||
Exchange
rate effect
|
--
|
--
%
|
|||||||||||
Operating
earnings
|
226
|
216
|
10
|
5
%
|
|||||||||
Asset
impairments and restructuring charges, net
|
2
|
--
|
2
|
||||||||||
Operating
earnings excluding asset impairments and restructuring charges,
net
|
228
|
216
|
12
|
6
%
|
PCI
Segment
|
||||||||||
Change
|
||||||||||
(Dollars
in millions)
|
2006
|
2005
|
$
|
%
|
||||||
Sales
|
$
|
1,659
|
$
|
1,560
|
$
|
99
|
6
%
|
|||
Volume
effect
|
1
|
--
%
|
||||||||
Price
effect
|
118
|
7
%
|
||||||||
Product
mix effect
|
(19)
|
(1)
%
|
||||||||
Exchange
rate effect
|
(1)
|
--
%
|
||||||||
Sales
– contract ethylene sales (1)
|
27
|
--
|
27
|
|||||||
Sales
– divested product lines (2)
|
111
|
104
|
7
|
|||||||
Sales
– excluding listed items
|
1,521
|
1,456
|
65
|
4
%
|
||||||
Volume
effect
|
(41)
|
(3)
%
|
||||||||
Price
effect
|
118
|
8
%
|
||||||||
Product
mix effect
|
(11)
|
(1)
%
|
||||||||
Exchange
rate effect
|
(1)
|
--
%
|
||||||||
Operating
earnings
|
132
|
143
|
(11)
|
(8)
%
|
||||||
Operating
earnings (loss) – divested product lines (2)(3)
|
(15)
|
--
|
(15)
|
--
%
|
||||||
Operating
earnings – excluding divested product lines (3)
|
147
|
143
|
(4)
|
(3)
%
|
||||||
Operating
earnings excluding certain items (3)(4)
|
161
|
154
|
7
|
5
%
|
||||||
Operating
earnings excluding certain items (4)
– divested product lines (2)(3)
|
3
|
3
|
--
|
--
%
|
||||||
Operating
earnings excluding certain items (4)
– excluding divested product lines (3)
|
158
|
151
|
7
|
5
%
|
|
(1)
Sales revenue for 2006 included contract ethylene sales under the
transition supply agreement related to the divestiture of the PE
businesses.
|
|
(2)
Sales revenue and operating results for 2006 and 2005 included sales
revenue from sales of products of the divested product lines of the
Company's Batesville, Arkansas manufacturing facility and related assets
and specialty organic chemicals product
lines.
|
|
(3)
Includes allocated costs consistent with the Company’s historical
practices, some of which may remain and could be reallocated to the
remainder of the segment and other
segments.
|
|
(4)
Items are accelerated depreciation costs, asset impairments and
restructuring charges, net and other operating charges,
net. Accelerated depreciation costs, asset impairments and
restructuring charges, and other operating charges for 2006 were $2
million, $20 million, and $7 million, respectively. Asset impairments and
restructuring charges for 2005 were $11 million related to previously
impaired sites. The other operating charges resulted from the
Batesville, Arkansas fourth quarter 2006
divestiture.
|
Performance
Polymers Segment
|
||||||||||
Change
|
||||||||||
(Dollars in
millions)
|
2006
|
2005
|
$
|
%
|
||||||
Sales
|
$
|
1,971
|
$
|
1,987
|
$
|
(16)
|
(1)
%
|
|||
Volume
effect
|
(38)
|
(2)
%
|
||||||||
Price
effect
|
12
|
1
%
|
||||||||
Product
mix effect
|
10
|
--
%
|
||||||||
Exchange
rate effect
|
--
|
--
%
|
||||||||
Sales
– divested PE product line (1)
|
635
|
618
|
17
|
3
%
|
||||||
Sales
from Mexico and Argentina PET manufacturing facilities (2)
|
440
|
427
|
13
|
3
%
|
||||||
Sales
- U.S. PET manufacturing facilities
|
896
|
942
|
(46)
|
(5)%
|
||||||
Volume
effect
|
(91)
|
(10)%
|
||||||||
Price
effect
|
37
|
4%
|
||||||||
Product
mix effect
|
8
|
1
%
|
||||||||
Exchange
rate effect
|
--
|
--
%
|
||||||||
Operating
earnings (3)
|
68
|
159
|
(91)
|
(57)
%
|
||||||
Operating
earnings – divested PE product line (1)
(4)
|
136
|
75
|
61
|
81
%
|
||||||
Operating
earnings (loss) - from sales from Mexico and
Argentina PET manufacturing facilities (2)(4)
|
(12)
|
24
|
(36)
|
(150)
%
|
||||||
Operating
earnings (loss) - U.S. PET manufacturing facilities (3)(4)
|
(56)
|
60
|
(116)
|
(193)
%
|
(1)
|
PE
product lines of the PE businesses and related assets located at the
Longview, Texas site which were sold in fourth quarter
2006.
|
(2)
|
Sales
revenue and operating results for 2006 and 2005 include sales revenue from
PET manufacturing facilities and related business in Cosoleacaque, Mexico
and Zarate, Argentina divested in fourth quarter 2007 These
sales are not presented as discontinued operations due to the Performance
Polymers segment's continuing involvement in the Latin American region and
raw material sales to the divested
facilities.
|
(3)
|
Includes
allocated costs not included in discontinued operations, some of which may
remain and could be reallocated to the remainder of the segment and other
segments.
|
(4)
|
Includes
allocated costs consistent with the Company's historical practices, some
of which may remain and could be reallocated to the remainder of the
segment and other segments.
|
Performance
Polymers Segment
|
||||||||
Change
|
||||||||
(Dollars
in millions)
|
2006
|
2005
|
$
|
%
|
||||
Operating
earnings excluding certain items (1)(2)
|
$
|
46
|
$
|
159
|
$
|
(113)
|
(71)
%
|
|
Operating
earnings excluding certain items (3)
- divested PE product line (4)
|
61
|
75
|
(14)
|
(19)
%
|
||||
Operating
earnings (loss) -
from sales from Mexico and Argentina PET manufacturing facilities (5)
|
(12)
|
24
|
(36)
|
(150)
%
|
||||
Operating
earnings (loss) excluding certain items (6)
- U.S. PET manufacturing facilities (1)
|
(3)
|
60
|
(63)
|
(105)
%
|
(1)
|
Includes
allocated costs not included in discontinued operations, some of which may
remain and could be reallocated to the remainder of the segment and other
segments.
|
(2)
|
Items
are accelerated depreciation costs and asset impairment and restructuring
charges, net. Asset impairments and restructuring charges of
$46 million for 2006 were primarily related to the shutdown of a research
and development pilot plant in Kingsport, Tennessee, discontinued
production of CHDM modified polymers in San Roque, Spain, and severance
costs from a reduction in force in the U.S. and Spain. CHDM, an
internal intermediate product primarily used in copolyester and PET
production, was discontinued in San Roque, Spain to gain operational
efficiencies at other facilities. Accelerated depreciation
costs of $7 million in 2006 related to the restructuring decisions in
association with cracking units in Longview, Texas, and higher cost PET
polymer intermediates assets in Columbia, South Carolina, which are
scheduled for shutdown. Other operating income was $75 million
in 2006 from the divestiture of the PE businesses and
assets.
|
(3)
|
Items
are other operating income from the sale of the PE businesses and related
assets located at the Longview, Texas site which were sold in fourth
quarter 2006, and which were $75 million in fourth quarter
2006.
|
(4)
|
PE
product lines of the PE businesses and related assets located at the
Longview, Texas site which were sold in fourth quarter
2006. Includes allocated costs consistent with the Company's
historical practices, some of which may remain and could be reallocated to
the remainder of the segment and other
segments.
|
(5)
|
Operating
results include operating results from PET manufacturing facilities
in Cosoleacaque, Mexico and Zarate, Argentina divested in fourth quarter
2007. These operating results are not presented as discontinued
operations due to the Performance Polymers segment's continuing
involvement in the Latin American region and raw material sales to the
divested facilities. Includes allocated costs consistent with
the Company's historical practices, some of which may remain and could be
reallocated to the remainder of the segment and other
segments.
|
(6)
|
Items
are accelerated depreciation costs and asset impairments and restructuring
charges (gains) related to the U.S. PET manufacturing
facilities. Asset impairments and restructuring charges were
$46 million and accelerated depreciation costs were $7 million in
2006.
|
SP
Segment
|
||||||||||
Change
|
||||||||||
(Dollars
in millions)
|
2006
|
2005
|
$
|
%
|
||||||
Sales
|
$
|
818
|
$
|
718
|
$
|
100
|
14
%
|
|||
Volume
effect
|
81
|
11
%
|
||||||||
Price
effect
|
34
|
5
%
|
||||||||
Product
mix effect
|
(11)
|
(1)
%
|
||||||||
Exchange
rate effect
|
(4)
|
(1)
%
|
||||||||
Operating
earnings
|
46
|
64
|
(18)
|
(28)
%
|
||||||
Accelerated
depreciation included in cost of goods sold
|
1
|
--
|
1
|
|||||||
Asset
impairments and restructuring charges, net
|
16
|
--
|
16
|
|||||||
Operating
earnings excluding accelerated depreciation costs and asset impairments
and restructuring charges, net
|
63
|
64
|
(1)
|
(2)
%
|
(Dollars
in millions)
|
2006
|
2005
|
Change
|
Volume
Effect
|
Price
Effect
|
Product
Mix
Effect
|
Exchange
Rate
Effect
|
|||||||
United
States and Canada
|
$
|
4,221
|
$
|
4,098
|
3
%
|
(1)
%
|
5
%
|
(1)
%
|
--
%
|
|||||
Europe,
Middle East, and Africa
|
816
|
753
|
8
%
|
3
%
|
5
%
|
1
%
|
(1)
%
|
|||||||
Asia
Pacific
|
941
|
930
|
1
%
|
(4)
%
|
8
%
|
(2)
%
|
(1)
%
|
|||||||
Latin
America
|
801
|
679
|
18
%
|
18
%
|
(1)
%
|
1
%
|
--
%
|
|||||||
$
|
6,779
|
$
|
6,460
|
5
%
|
1
%
|
5
%
|
(1)
%
|
--
%
|
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Net
cash provided by (used in):
|
||||||
Operating
activities
|
$
|
732
|
$
|
609
|
$
|
769
|
Investing
activities
|
(335)
|
(94)
|
(18)
|
|||
Financing
activities
|
(448)
|
(101)
|
(547)
|
|||
Effect
of exchange rate changes on cash and cash equivalents
|
--
|
1
|
(5)
|
|||
Net
change in cash and cash equivalents
|
$
|
(51)
|
$
|
415
|
$
|
199
|
Cash
and cash equivalents at end of period
|
$
|
888
|
$
|
939
|
$
|
524
|
(Dollars
in millions)
|
Payments
Due for
|
|||||||||||||
Period
|
Notes
and Debentures
|
Credit
Facility Borrowings and Other
|
Interest
Payable
|
Purchase
Obligations
|
Operating
Leases
|
Other
Liabilities (a)
|
Total
|
|||||||
2008
|
$
|
72
|
$
|
--
|
$
|
98
|
$
|
508
|
$
|
32
|
$
|
148
|
$
|
858
|
2009
|
--
|
14
|
96
|
460
|
26
|
73
|
669
|
|||||||
2010
|
--
|
--
|
96
|
420
|
22
|
70
|
608
|
|||||||
2011
|
2
|
--
|
96
|
253
|
20
|
59
|
430
|
|||||||
2012
|
148
|
188
|
84
|
246
|
12
|
55
|
733
|
|||||||
2013
and beyond
|
1,183
|
--
|
945
|
403
|
65
|
653
|
3,249
|
|||||||
Total
|
$
|
1,405
|
$
|
202
|
$
|
1,415
|
$
|
2,290
|
$
|
177
|
$
|
1,058
|
$
|
6,547
|
·
|
to
maintain strong volumes due to continued substitution of Eastman products
for other materials, and new applications for existing
products despite uncertain prospects for the U.S. and global
economies;
|
·
|
the
volatility of raw material and energy costs to continue and that the
Company will continue to use pricing strategies and ongoing cost control
initiatives to offset the effects on gross
profit;
|
·
|
to
improve the profitability of its PET product lines in the Performance
Polymers segment, including completing the divestiture of its
underperforming PET manufacturing facilities outside the United States;
debottlenecking the new South Carolina PET facility utilizing
IntegRexTM technology by the
end of 2008 for a total capacity of 525,000 metric tons of ParaStarTM
PET; shutting down another 300,000 metric tons of conventional PET
polymers capacity at the South Carolina manufacturing facility by
mid-year; eliminating approximately $30 million of annual costs at the
South Carolina site by the middle of 2008; and continuing to pursue
options to create additional value from its IntegRexTM technology,
primarily by actively pursing licensing
opportunities;
|
·
|
to
improve SP segment results by completing the conversion of 50,000 metric
tons of PET capacity to copolyester by the middle of 2008 and continue
progress with the commercialization of its new copolyester, Eastman
TritanTM
copolyester;
|
·
|
that
the staged phase-out of older cracking units in Longview, Texas and a
planned shut down of higher cost PET assets in Columbia, South Carolina
will result in accelerated depreciation costs of approximately $10
million;
|
·
|
ethylene
volumes to decline in the PCI segment due to the staged phase-out of older
cracking units at the Company's Longview, Texas
facility;
|
·
|
modest
sales volume growth for acetate tow in the Fibers segment, to complete the
expansion of its acetate tow plant in Workington, England, in the second
half of 2008, and to announce plans for new acetate tow capacity in
Asia;
|
·
|
the
PCI segment to have operating margins at the high end of the 5 to 10
percent range;
|
·
|
the
CASPI segment to maintain solid earnings at the low end of the 15 to
20 percent operating margin range and expects continued weakness in the
U.S. housing and automotive sectors to be
offset by strength in Europe and
Asia;
|
·
|
front-end
engineering and design for its two industrial gasification projects in
Beaumont, Texas, and St. James Parish, Louisiana to be completed in the
second half of 2008, and project financing to be obtained by the end of
the year;
|
·
|
net
interest expense to increase compared with 2007 primarily due to lower
interest income, driven by declining interest
rates;
|
·
|
the
effective tax rate to be approximately 34
percent;
|
·
|
capital
spending will be above $600 million as it funds targeted growth efforts,
including the debottlenecking of the South Carolina manufacturing
facility utilizing IntegRexTM
technology, the completion of front-end engineering and design for the two
industrial gasification projects, increased capacity of CTA for LCD
screens, increased capacity for Eastman TritanTM
copolyester, and the completion of the acetate tow expansion in
Workington, England; and
|
·
|
priorities
for uses of available cash to be to pay the quarterly cash dividend, fund
targeted growth initiatives, and repurchase
shares.
|
·
|
its
industrial gasification projects in Texas and Louisiana to break
ground in early 2009, with the facilities online by 2011, and expects
these projects to contribute significantly to earnings in
2012;
|
·
|
the
SP segment further to improve earnings by completing the conversion of an
additional 50,000 metric tons of PET to be converted by 2010, increasing
sales revenue from cellulose esters used in LCD screens and continued
progress with the commercialization of its high performance
copolyesters;
|
·
|
to
pursue licensing opportunities for the PCI segment's acetyl and oxo
technologies and for the Performance Polymers segment's IntegRexTM technology;
|
·
|
to
pursue growth opportunities in Asia for acetate tow in the Fibers segment;
and
|
·
|
to
complete an additional 30 percent expansion of its CASPI segment's
hydrogenated hydrocarbon resins manufacturing capacity in Middelburg, the
Netherlands in early 2009.
|
·
|
The
Company is reliant on certain strategic raw materials and energy
commodities for its operations and utilizes risk management tools,
including hedging, as appropriate, to mitigate short-term market
fluctuations in raw material and energy costs. There can be no
assurance, however, that such measures will result in cost savings or that
all market fluctuation exposure will be eliminated. In
addition, natural disasters, changes in laws or regulations, war or other
outbreak of hostilities or terrorism or other political factors in any of
the countries or regions in which the Company operates or does business or
in countries or regions that are key suppliers of strategic raw materials
and energy commodities, or breakdown or degradation of transportation
infrastructure used for delivery of strategic raw materials and energy
commodities, could affect availability and costs of raw materials and
energy commodities.
|
·
|
While
temporary shortages of raw materials and energy may occasionally occur,
these items have historically been sufficiently available to cover current
and projected requirements. However, their continuous
availability and price are impacted by natural disasters, plant
interruptions occurring during periods of high demand, domestic and world
market and political conditions, changes in government regulation, war or
other outbreak of hostilities or terrorism, and breakdown or degradation
of transportation infrastructure. Eastman’s operations or
products may, at times, be adversely affected by these
factors.
|
·
|
The
Company's competitive position in the markets in which it participates is,
in part, subject to external factors in addition to those that the Company
can impact. Natural disasters, pandemic illnesses, changes in
laws or regulations, war or other outbreak of hostilities or terrorism, or
other political factors in any of the countries or regions in which the
Company operates or does business or in countries or regions that are key
suppliers of strategic raw materials, and breakdown or degradation of
transportation infrastructure used for delivery of raw
materials and energy supplies to the Company and for delivery of the
Company's products to customers, could negatively impact the Company’s
competitive position and its ability to maintain market
share. For example, supply and demand for certain of the
Company's products is driven by end-use markets and worldwide capacities
which, in turn, impact demand for and pricing of the Company's
products.
|
·
|
Limitation
of the Company's available manufacturing capacity due to significant
disruption in its manufacturing operations, including natural disasters,
pandemic illnesses, changes in laws or regulations, war or other outbreak
of hostilities or terrorism, or other political factors in any of the
countries or regions in which the Company operates or does business, or
breakdown or degradation of transportation infrastructure used for
delivery of raw materials and energy supplies to the Company
and for delivery of the Company's products to customers, could have a
material adverse affect on sales revenue, costs and results of operations
and financial condition.
|
·
|
The
Company has an extensive customer base; however, loss of, or material
financial weakness of, certain of the largest customers could adversely
affect the Company's financial condition and results of operations until
such business is replaced and no assurances can be made that the Company
would be able to regain or replace any lost
customers.
|
·
|
The
Company has efforts underway to exploit growth opportunities in certain
core businesses by developing new products and technologies, expanding
into new markets, and tailoring product offerings to customer
needs. Current examples include IntegRexTM
technology and new PET polymers products and copolyester product
innovations. There can be no assurance that such efforts will result in
financially successful commercialization of such products or acceptance by
existing or new customers or new markets or that large capital projects
for such growth efforts can be completed within the time or at the costs
projected due, among other things, to demand for and availability of
construction materials and labor.
|
·
|
The
Company has made, and intends to continue making, strategic investments,
including industrial gasification, and has entered, and expects to
continue to enter, into strategic alliances in technology, services
businesses, and other ventures in order to build, diversify, and
strengthen certain Eastman capabilities, improve Eastman's raw materials
and energy cost and supply position, and maintain high utilization of
manufacturing assets. There can be no assurance that such
investments and alliances will achieve their underlying strategic business
objectives or that they will be beneficial to the Company's results of
operations or that large capital projects for such growth efforts can be
completed within the time or at the costs projected due, among other
things, to demand for and availability of construction materials and labor
and obtaining regulatory approvals and operating permits and
reaching agreement on terms of key agreements and arrangements with
potential suppliers and customers. Such delays or cost overruns or
inability to obtain such approvals or to reach such agreements on
acceptable terms could negatively affect the returns from these strategic
investments and projects.
|
·
|
The
Company anticipates obtaining non-recourse financing for the two
industrial gasification projects. There is risk that such financing cannot
be obtained or if, obtained, may be on terms different than those assumed
in the Company's projections for financial performance of the projects,
due to any circumstance, change, or condition in the loan syndication,
financial, or capital markets generally that could reasonably be expected
to materially affect availability, terms, and syndication of such
financing. The ability to enter into financially acceptable
project commercial agreements for such elements as engineering,
procurement, and construction, off-take agreements, commodity and/or
interest hedges, utilities, administrative services, and others, as well
as obtaining all necessary regulatory approvals and operating permits, may
impact the available financing for the projects or the terms of such
financing, if available, including the nature and terms of any recourse
back to the Company or other project equity
owners.
|
·
|
In
addition to productivity and cost reduction initiatives, the Company is
striving to improve margins on its products through price increases where
warranted and accepted by the market; however, the Company's earnings
could be negatively impacted should such increases be unrealized, not be
sufficient to cover increased raw material and energy costs, or have a
negative impact on demand and volume. There can be no
assurances that price increases will be realized or will be realized
within the Company's anticipated
timeframe.
|
·
|
The
Company has undertaken and expects to continue to undertake productivity
and cost reduction initiatives and organizational restructurings to
improve performance and generate cost savings. There can be no
assurance that these will be completed as planned or beneficial or that
estimated cost savings from such activities will be
realized.
|
·
|
The
Company's facilities and businesses are subject to complex health, safety
and environmental laws and regulations, which require and will continue to
require significant expenditures to remain in compliance with such laws
and regulations currently and in the future. The Company's
accruals for such costs and associated liabilities are subject to changes
in estimates on which the accruals are based. The amount
accrued reflects the Company’s assumptions about remediation requirements
at the contaminated site, the nature of the remedy, the outcome of
discussions with regulatory agencies and other potentially responsible
parties at multi-party sites, and the number and financial viability of
other potentially responsible parties. Changes in the estimates
on which the accruals are based, unanticipated government enforcement
action, or changes in health, safety, environmental, chemical control
regulations, and testing requirements could result in higher or lower
costs.
|
·
|
The
Company and its operations from time to time are parties to or targets of
lawsuits, claims, investigations, and proceedings, including product
liability, personal injury, asbestos, patent and intellectual property,
commercial, contract, environmental, antitrust, health and safety, and
employment matters, which are handled and defended in the ordinary course
of business. The Company believes amounts reserved are adequate
for such pending matters; however, results of operations could be affected
by significant litigation adverse to the
Company.
|
·
|
The
Company has deferred tax assets related to capital and operating
losses. The Company establishes valuation allowances to reduce
these deferred tax assets to an amount that is more likely than not to be
realized. The Company’s ability to utilize these deferred tax
assets depends on projected future operating results, the reversal of
existing temporary differences, and the availability of tax planning
strategies. Realization of these assets is expected to occur
over an extended period of time. As a result, changes in tax laws,
assumptions with respect to future taxable income, and tax planning
strategies could result in adjustments to these
assets.
|
·
|
Due
to the Company's global sales, earnings, and asset profile, it is exposed
to volatility in foreign currency exchange rates and interest
rates. The Company may use derivative financial instruments,
including swaps, options and forwards, to mitigate the impact of changes
in exchange rates and interest rates on its financial
results. However, there can be no assurance that these efforts
will be successful and operating results could be affected by significant
adverse changes in currency exchange rates or interest
rates.
|
ITEM
|
Page
|
77
|
|
78
|
|
80
|
|
81
|
|
82
|
|
83
|
|
89
|
|
90
|
|
91
|
|
91
|
|
92
|
|
92
|
|
93
|
|
94
|
|
94
|
|
96
|
|
103
|
|
105
|
|
105
|
|
106
|
|
108
|
|
112
|
|
114
|
|
116
|
|
117
|
|
117
|
|
120
|
|
121
|
|
125
|
|
127
|
|
129
|
|
/s/ J. Brian Ferguson
|
/s/
Richard A. Lorraine
|
|
J.
Brian Ferguson
|
Richard
A. Lorraine
|
|
Chairman
of the Board and
|
Senior
Vice President and
|
|
Chief
Executive Officer
|
Chief
Financial Officer
|
|
February 28 ,
2008
|
For
years ended December 31,
|
||||||
(Dollars
in millions, except per share amounts)
|
2007
|
2006
|
2005
|
|||
Sales
|
$
|
6,830
|
$
|
6,779
|
$
|
6,460
|
Cost
of sales
|
5,638
|
5,514
|
5,100
|
|||
Gross
profit
|
1,192
|
1,265
|
1,360
|
|||
Selling,
general and administrative expenses
|
420
|
423
|
439
|
|||
Research
and development expenses
|
156
|
155
|
150
|
|||
Asset
impairments and restructuring charges, net
|
112
|
101
|
33
|
|||
Other
operating income, net
|
--
|
(68)
|
(2)
|
|||
Operating
earnings
|
504
|
654
|
740
|
|||
Interest
expense, net
|
62
|
77
|
100
|
|||
Income
from equity investment in Genencor
|
--
|
--
|
(173)
|
|||
Early
debt extinguishment costs
|
--
|
--
|
46
|
|||
Other
(income) charges, net
|
(28)
|
(17)
|
4
|
|||
Earnings
from continuing operations before income taxes
|
470
|
594
|
763
|
|||
Provision
(benefit) for income taxes from continuing operations
|
149
|
167
|
222
|
|||
Earnings
from continuing operations
|
321
|
427
|
541
|
|||
Earnings
(loss) from discontinued operations, net of tax
|
(10)
|
(18)
|
16
|
|||
Loss
from disposal of discontinued operations, net of tax
|
(11)
|
--
|
--
|
|||
Net
earnings
|
$
|
300
|
$
|
409
|
$
|
557
|
Basic
earnings per share
|
||||||
Earnings
from continuing operations
|
$
|
3.89
|
$
|
5.20
|
$
|
6.70
|
Earnings
(loss) from discontinued operations
|
(0.26)
|
(0.22)
|
0.20
|
|||
Basic
earnings per share
|
$
|
3.63
|
$
|
4.98
|
$
|
6.90
|
Diluted
earnings per share
|
||||||
Earnings
from continuing operations
|
$
|
3.84
|
$
|
5.12
|
$
|
6.61
|
Earnings
(loss) from discontinued operations
|
(0.26)
|
(0.21)
|
0.20
|
|||
Diluted
earnings per share
|
$
|
3.58
|
$
|
4.91
|
$
|
6.81
|
Comprehensive
Income
|
||||||
Net
earnings
|
$
|
300
|
$
|
409
|
$
|
557
|
Other
comprehensive income (loss)
|
||||||
Change
in cumulative translation adjustment, net of tax
|
36
|
60
|
(94)
|
|||
Change
in pension liability, net of tax
|
15
|
48
|
(7)
|
|||
Change
in unrealized gains (losses) on derivative instruments, net of
tax
|
3
|
(1)
|
3
|
|||
Change
in unrealized gains on investments, net of tax
|
1
|
--
|
1
|
|||
Total
other comprehensive income (loss)
|
55
|
107
|
( 97)
|
|||
Comprehensive
income
|
$
|
355
|
$
|
516
|
$
|
460
|
Retained
Earnings
|
||||||
Retained
earnings at beginning of period
|
$
|
2,186
|
$
|
1,923
|
$
|
1,509
|
Net
earnings
|
300
|
409
|
557
|
|||
Cash
dividends declared
|
(145)
|
(146)
|
(143)
|
|||
Effect
of adoption of FIN 48
|
8
|
--
|
--
|
|||
Retained
earnings at end of period
|
$
|
2,349
|
$
|
2,186
|
$
|
1,923
|
December
31,
|
December
31,
|
|||
(Dollars
in millions, except per share amounts)
|
2007
|
2006
|
||
Assets
|
||||
Current
assets
|
||||
Cash
and cash equivalents
|
$
|
888
|
$
|
939
|
Trade
receivables, net of allowance of $6 and $15
|
546
|
682
|
||
Miscellaneous
receivables
|
112
|
72
|
||
Inventories
|
539
|
682
|
||
Other
current assets
|
74
|
47
|
||
Current
assets held for sale
|
134
|
--
|
||
Total
current assets
|
2,293
|
2,422
|
||
Properties
|
||||
Properties
and equipment at cost
|
8,152
|
8,844
|
||
Less: Accumulated
depreciation
|
5,306
|
5,775
|
||
Net
properties
|
2,846
|
3,069
|
||
Goodwill
|
316
|
314
|
||
Other
noncurrent assets
|
313
|
327
|
||
Noncurrent
assets held for sale
|
241
|
--
|
||
Total
assets
|
$
|
6,009
|
$
|
6,132
|
Liabilities
and Stockholders’ Equity
|
||||
Current
liabilities
|
||||
Payables
and other current liabilities
|
$
|
1,013
|
$
|
1,056
|
Borrowings
due within one year
|
72
|
3
|
||
Current
liabilities related to assets held for sale
|
37
|
--
|
||
Total
current liabilities
|
1,122
|
1,059
|
||
Long-term
borrowings
|
1,535
|
1,589
|
||
Deferred
income tax liabilities
|
300
|
269
|
||
Post-employment
obligations
|
852
|
1,084
|
||
Other
long-term liabilities
|
118
|
102
|
||
Total
liabilities
|
3,927
|
4,103
|
||
Stockholders’
equity
|
||||
Common
stock ($0.01 par value – 350,000,000 shares authorized; shares issued –
93,630,292 and 91,579,294 for 2007 and 2006, respectively)
|
1
|
1
|
||
Additional
paid-in capital
|
573
|
448
|
||
Retained
earnings
|
2,349
|
2,186
|
||
Accumulated
other comprehensive loss
|
(28)
|
(174)
|
||
2,895
|
2,461
|
|||
Less:
Treasury stock at cost (13,959,951 shares for 2007 and 8,048,442 shares
for 2006)
|
813
|
432
|
||
Total
stockholders’ equity
|
2,082
|
2,029
|
||
Total
liabilities and stockholders’ equity
|
$
|
6,009
|
$
|
6,132
|
For
years ended December 31,
|
||||||
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Cash
flows from operating activities
|
||||||
Net
earnings
|
$
|
300
|
$
|
409
|
$
|
557
|
Adjustments
to reconcile net earnings to net cash provided by operating
activities:
|
||||||
Depreciation
and amortization
|
327
|
308
|
304
|
|||
Asset
impairments
|
138
|
62
|
12
|
|||
Gains
on sale of assets
|
(8)
|
(74)
|
--
|
|||
Income
from equity investment in Genencor
|
--
|
--
|
(173)
|
|||
Early
debt extinguishment costs
|
--
|
--
|
46
|
|||
Provision
(benefit) for deferred income taxes
|
(9)
|
7
|
115
|
|||
Changes
in operating assets and liabilities, net of effect of acquisitions and
divestitures:
|
||||||
(Increase)
decrease in trade receivables
|
(28)
|
(82)
|
60
|
|||
(Increase)
decrease in inventories
|
66
|
(99)
|
(110)
|
|||
Increase
(decrease) in trade payables
|
48
|
53
|
71
|
|||
Increase
(decrease) in liabilities for employee benefits and incentive
pay
|
(55)
|
(44)
|
(63)
|
|||
Other
items, net
|
(47)
|
69
|
(50)
|
|||
Net
cash provided by operating activities
|
732
|
609
|
769
|
|||
Cash
flows from investing activities
|
||||||
Additions
to properties and equipment
|
(518)
|
(389)
|
(343)
|
|||
Proceeds
from sale of assets and investments
|
202
|
322
|
50
|
|||
Proceeds
from the sale of equity investment in Genencor, net
|
--
|
--
|
417
|
|||
Acquisitions
and investments in joint ventures
|
(40)
|
--
|
(125)
|
|||
Additions
to capitalized software
|
(11)
|
(16)
|
(11)
|
|||
Other
items, net
|
32
|
(11)
|
(6)
|
|||
Net
cash used in investing activities
|
(335)
|
(94)
|
(18)
|
|||
Cash
flows from financing activities
|
||||||
Net
decrease in commercial paper, credit facility, and other
borrowings
|
(22)
|
(50)
|
(150)
|
|||
Proceeds
from long-term borrowings
|
--
|
--
|
189
|
|||
Repayment
of long-term borrowings
|
--
|
--
|
(544)
|
|||
Dividends
paid to stockholders
|
(147)
|
(144)
|
(142)
|
|||
Treasury
stock purchases
|
(382)
|
--
|
--
|
|||
Proceeds
from stock option exercises and other items
|
103
|
93
|
100
|
|||
Net
cash used in financing activities
|
(448)
|
(101)
|
(547)
|
|||
Effect
of exchange rate changes on cash and cash equivalents
|
--
|
1
|
(5)
|
|||
Net
change in cash and cash equivalents
|
(51)
|
415
|
199
|
|||
Cash
and cash equivalents at beginning of period
|
939
|
524
|
325
|
|||
Cash
and cash equivalents at end of period
|
$
|
888
|
$
|
939
|
$
|
524
|
(Dollars
in millions, except per share amounts)
|
2005
|
||
Earnings
from continuing operations, as reported
|
$
|
541
|
|
Add: Stock-based
employee compensation expense included in earnings from continuing
operations, as reported
|
10
|
||
Deduct: Total
additional stock-based employee compensation cost, net of tax, that would
have been included in earnings from continuing operations under fair value
method
|
14
|
||
Pro
forma earnings from continuing operations
|
$
|
537
|
|
Basic
earnings from continuing operations per share
|
As
reported
|
$6.70
|
|
Pro
forma
|
$6.65
|
||
Diluted
earnings from continuing operations per share
|
As
reported
|
$6.61
|
|
Pro
forma
|
$6.57
|
DISCONTINUED
OPERATIONS AND ASSETS HELD FOR SALE
|
For
years ended December 31,
|
||||||
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Sales
|
$
|
542
|
$
|
671
|
$
|
599
|
Earnings
(loss) before income taxes
|
(9)
|
(18)
|
20
|
|||
Earnings
(loss) from discontinued operations, net of tax
|
(10)
|
(18)
|
16
|
|||
Loss
on disposal, net of tax
|
(11)
|
--
|
--
|
December
31,
|
||
(Dollars
in millions)
|
2007
|
|
Current
assets
|
||
Trade
receivables
|
$
|
85
|
Inventories
|
49
|
|
Total
current assets held for sale
|
134
|
|
Non-current
assets
|
||
Properties
and equipment, net
|
236
|
|
Other
non-current assets
|
5
|
|
Total
non-current assets held for sale
|
241
|
|
Total
assets
|
$
|
375
|
Current
liabilities
|
||
Payables
and other current liabilities, net
|
$
|
37
|
Total
current liabilities held for sale
|
37
|
|
Total
liabilities
|
$
|
37
|
INVENTORIES
|
December
31,
|
||||
(Dollars
in millions)
|
2007
|
2006
|
||
At
FIFO or average cost (approximates current cost)
|
||||
Finished
goods
|
$
|
607
|
$
|
660
|
Work
in process
|
195
|
206
|
||
Raw
materials and supplies
|
247
|
280
|
||
Total
inventories
|
1,049
|
1,146
|
||
LIF O
Reserve
|
(510)
|
(464)
|
||
Total
inventories
|
$
|
539
|
$
|
682
|
PROPERTIES
AND ACCUMULATED DEPRECIATION
|
December
31,
|
||||
(Dollars
in millions)
|
2007
|
2006
|
||
Properties
|
||||
Land
|
$
|
46
|
$
|
42
|
Buildings
and building equipment
|
782
|
824
|
||
Machinery
and equipment
|
7,009
|
7,819
|
||
Construction
in progress
|
315
|
159
|
||
Properties
and equipment at cost
|
$
|
8,152
|
$
|
8,844
|
Less: Accumulated
depreciation
|
5,306
|
5,775
|
||
Net
properties
|
$
|
2,846
|
$
|
3,069
|
GOODWILL
AND OTHER INTANGIBLE ASSETS
|
(Dollars
in millions)
|
CASPI
Segment
|
Other
Segments
|
Total
Eastman Chemical
|
|||
Reported
balance at December 31, 2005
|
$
|
306
|
$
|
6
|
$
|
312
|
Currency
translation adjustments
|
2
|
--
|
2
|
|||
Reported
balance at December 31, 2006
|
308
|
6
|
314
|
|||
Currency
translation adjustments
|
2
|
--
|
2
|
|||
Reported
balance at December 31, 2007
|
$
|
310
|
$
|
6
|
$
|
316
|
EQUITY
INVESTMENTS
|
PAYABLES
AND OTHER CURRENT
LIABILITIES
|
December
31,
|
||||
(Dollars
in millions)
|
2007
|
2006
|
||
Trade
creditors
|
$
|
578
|
$
|
581
|
Accrued
payrolls, vacation, and variable-incentive compensation
|
138
|
126
|
||
Accrued
taxes
|
36
|
59
|
||
Post-employment
obligations
|
60
|
63
|
||
Interest
payable
|
31
|
31
|
||
Bank
overdrafts
|
6
|
11
|
||
Other
|
164
|
185
|
||
Total
payables and other current liabilities
|
$
|
1,013
|
$
|
1,056
|
BORROWINGS
|
December
31,
|
||||
(Dollars
in millions)
|
2007
|
2006
|
||
Borrowings
consisted of:
|
||||
3
1/4% notes due 2008
|
$
|
72
|
$
|
72
|
6.30%
notes due 2018
|
188
|
182
|
||
7%
notes due 2012
|
148
|
141
|
||
7
1/4% debentures due 2024
|
497
|
497
|
||
7
5/8% debentures due 2024
|
200
|
200
|
||
7.60%
debentures due 2027
|
298
|
297
|
||
Credit
facility borrowings
|
188
|
185
|
||
Other
|
16
|
18
|
||
Total
borrowings
|
1,607
|
1,592
|
||
Borrowings
due within one year
|
(72)
|
(3)
|
||
Long-term
borrowings
|
$
|
1,535
|
$
|
1,589
|
EARLY
EXTINGUISHMENT OF DEBT
|
(Dollars
in millions)
|
Book
Value
|
|
3
1/4% notes due 2008
|
$
|
178
|
6.30%
notes due 2018
|
68
|
|
7%
notes due 2012
|
254
|
|
Total
|
$
|
500
|
FAIR
VALUE OF FINANCIAL INSTRUMENTS
|
December
31, 2007
|
December
31, 2006
|
|||||||
(Dollars
in millions)
|
Recorded
Amount
|
Fair
Value
|
Recorded
Amount
|
Fair
Value
|
||||
Long-term
borrowings
|
$
|
1,535
|
$
|
1,637
|
$
|
1,589
|
$
|
1,715
|
RETIREMENT
PLANS
|
December
31, 2006
|
||||||
(Dollars
in millions)
|
Pre-SFAS
No.
158
|
Adjustment
to initially apply FAS 158
|
Post
SFAS
No.
158 Adjustment
|
|||
Intangible
asset
|
$ |
21
|
$
|
(21)
|
$
|
--
|
Deferred
tax asset
|
119
|
42
|
161
|
|||
Accrued
pension liability
|
(241)
|
(105)
|
(346)
|
|||
Accumulated
other comprehensive loss, net of tax
|
(207)
|
(84)
|
(291)
|
|||
Summary
Balance Sheet
|
||||
(Dollars
in millions)
|
2007
|
2006
|
||
Change
in projected benefit obligation:
|
||||
Benefit
obligation, beginning of year
|
$
|
1,593
|
$
|
1,477
|
Service
cost
|
48
|
44
|
||
Interest
cost
|
90
|
82
|
||
Actuarial
(gain)/loss
|
(58)
|
12
|
||
Plan
amendments and other
|
(55)
|
71
|
||
Effect
of currency exchange
|
16
|
26
|
||
Benefits
paid
|
(164)
|
(119)
|
||
Benefit
obligation, end of year
|
$
|
1,470
|
$
|
1,593
|
Change
in plan assets:
|
||||
Fair
value of plan assets, beginning of year
|
$
|
1,247
|
$
|
1,054
|
Actual
return on plan assets
|
115
|
162
|
||
Plan
amendments and other
|
1
|
46
|
||
Effect
of currency exchange
|
12
|
17
|
||
Company
contributions
|
135
|
87
|
||
Benefits
paid
|
(164)
|
(119)
|
||
Fair
value of plan assets, end of year
|
$
|
1,346
|
$
|
1,247
|
Funded
Status at end of year
|
$
|
(124)
|
$
|
(346)
|
Amounts
recognized in the Statements of Financial Position consist
of:
|
||||
Noncurrent
Asset
|
$
|
2
|
$
|
--
|
Current
liability
|
(3)
|
(3)
|
||
Noncurrent
liability
|
(123)
|
(343)
|
||
Net
amount recognized, end of year
|
$
|
(124)
|
$
|
(346)
|
Amounts
recognized in accumulated other comprehensive income consist
of:
|
||||
Net
actuarial loss (gain)
|
$
|
360
|
$
|
462
|
Prior
service costs (credit)
|
(58)
|
(10)
|
||
Accumulated
other comprehensive loss
|
$
|
302
|
$
|
452
|
Summary
of Benefit Costs and Other Amounts Recognized in Other Comprehensive
Income
|
||||||
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Components
of net periodic benefit cost:
|
||||||
Service
cost
|
$
|
48
|
$
|
44
|
$
|
43
|
Interest
cost
|
90
|
82
|
80
|
|||
Expected
return on assets
|
(105)
|
(88)
|
(79)
|
|||
Curtailment
charge
|
4
|
--
|
--
|
|||
Amortization
of:
|
||||||
Prior
service credit
|
(9)
|
(10)
|
(9)
|
|||
Actuarial
loss
|
35
|
39
|
36
|
|||
Net
periodic benefit cost
|
$
|
63
|
$
|
67
|
$
|
71
|
Other
changes in plan assets and benefit obligations recognized in other
comprehensive income:
|
||||||
Curtailment
effect
|
$
|
10
|
$
|
--
|
$
|
--
|
Current
year actuarial gains
|
68
|
--
|
--
|
|||
Current
year prior service credit
|
49
|
|||||
Amortization
of:
|
||||||
Prior
service credit
|
(9)
|
(10)
|
(10)
|
|||
Actuarial
loss
|
35
|
39
|
36
|
|||
Effect
of currency exchange
|
(3)
|
--
|
--
|
|||
Total
|
$
|
150
|
$
|
29
|
$
|
26
|
2007
|
2006
|
2005
|
|||
Weighted-average
assumptions used to determine benefit obligations for years ended December
31:
|
|||||
Discount
rate
|
6.03%
|
5.66%
|
5.51%
|
||
Expected
return on assets
|
8.57%
|
8.53%
|
8.59%
|
||
Rate
of compensation increase
|
3.83%
|
3.78%
|
3.75%
|
||
Weighted-average
assumptions used to determine net periodic pension cost for years ended
December 31:
|
|||||
Discount
rate
|
5.66%
|
5.51%
|
5.67%
|
||
Expected
return on assets
|
8.53%
|
8.59%
|
8.65%
|
||
Rate
of compensation increase
|
3.78%
|
3.75%
|
3.78%
|
||
Target
Allocation
|
Plan
Assets at December 31,
2007
|
Plan
Assets at December 31, 2006
|
|
Asset
category
|
|||
Equity
securities
|
59%
|
69%
|
75%
|
Debt
securities
|
12%
|
9%
|
8%
|
Real
estate
|
9%
|
8%
|
5%
|
Other
investments
|
20%
|
14%
|
12%
|
Total
|
100%
|
100%
|
100%
|
Target
Allocation
|
Plan
Assets at December 31,
2007
|
Plan
Assets at December 31, 2006
|
|
Asset
category
|
|||
Equity
securities
|
34%
|
34%
|
35%
|
Debt
securities
|
57%
|
57%
|
56%
|
Other
investments
|
9%
|
9%
|
9%
|
Total
|
100%
|
100%
|
100%
|
(Dollars
in millions)
|
2008
|
2009
|
2010
|
2011
|
2012
|
2013-2017
|
U.S.
plan
|
$90
|
$90
|
$93
|
$99
|
$105
|
$627
|
International
plans
|
$6
|
$6
|
$6
|
$7
|
$7
|
$46
|
Summary
Balance Sheet
|
||||
(Dollars
in millions)
|
2007
|
2006
|
||
Change
in benefit obligation:
|
||||
Benefit
obligation, beginning of year
|
$
|
731
|
$
|
779
|
Service
cost
|
7
|
8
|
||
Interest
cost
|
43
|
41
|
||
Plan
participants’ contributions
|
16
|
18
|
||
Actuarial
(gain) loss
|
(16)
|
(57)
|
||
Benefits
paid
|
(59)
|
(58)
|
||
Plan
amendments
|
(6)
|
--
|
||
Benefit
obligation, end of year
|
$
|
716
|
$
|
731
|
Change
in plan assets:
|
||||
Fair
value of plan assets, beginning of year
|
$
|
57
|
$
|
6
|
Actual
return on plan assets
|
2
|
1
|
||
Company
contributions
|
37
|
34
|
||
Third
party contributions
|
--
|
95
|
||
Reserve
for third party contributions
|
3
|
(39)
|
||
Plan
participants’ contributions
|
16
|
18
|
||
Benefits
paid
|
(59)
|
(58)
|
||
Fair
value of plan assets, end of year
|
$
|
56
|
$
|
57
|
Funded
status
|
$
|
(660)
|
$
|
(674)
|
Amounts
recognized in the Statements of Financial Position consist
of:
|
||||
Current
liabilities
|
$
|
(40)
|
$
|
(38)
|
Non-current
liabilities
|
(620)
|
(636)
|
||
Net
amount recognized, end of year
|
$
|
(660)
|
$
|
(674)
|
Amounts
recognized in accumulated other comprehensive income consist
of:
|
||||
Actuarial
(gain) loss
|
$
|
176
|
$
|
206
|
Prior
service (credit) cost
|
(194)
|
(211)
|
||
Accumulated
other comprehensive income
|
$
|
(18)
|
$
|
(5)
|
Summary
of Benefit Costs
|
||||||
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Components
of net periodic benefit cost:
|
||||||
Service
cost
|
$
|
7
|
$
|
8
|
$
|
8
|
Interest
cost
|
43
|
41
|
43
|
|||
Expected
return on assets
|
(3)
|
--
|
--
|
|||
Other
|
--
|
(12)
|
--
|
|||
Amortization
of:
|
||||||
Prior
service credit
|
(23)
|
(22)
|
(23)
|
|||
Actuarial
loss
|
12
|
15
|
20
|
|||
Net
periodic benefit cost
|
$
|
36
|
$
|
30
|
$
|
48
|
Weighted-average
assumptions used to determine end of year benefit
obligations:
|
2007
|
2006
|
2005
|
||
Discount
rate
|
6.19%
|
5.86%
|
5.62%
|
||
Rate
of compensation increase
|
3.75%
|
3.75%
|
3.75%
|
||
Health
care cost trend
|
|||||
Initial
|
9.00%
|
9.00%
|
8.00%
|
||
Decreasing
to ultimate trend of
|
5.00%
|
5.00%
|
5.00%
|
||
in
year
|
2012
|
2011
|
2009
|
Weighted-average
assumptions used to determine end of year net benefit
cost:
|
2007
|
2006
|
2005
|
||
Discount
rate
|
5.86%
|
5.62%
|
5.75%
|
||
Rate
of compensation increase
|
3.75%
|
3.75%
|
3.75%
|
||
Health
care cost trend
|
|||||
Initial
|
9.00%
|
8.00%
|
9.00%
|
||
Decreasing
to ultimate trend of
|
5.00%
|
5.00%
|
5.00%
|
||
in
year
|
2011
|
2009
|
2009
|
2008
|
2009
|
2010
|
2011
|
2012
|
2013-2017
|
|
U.S.
plans
|
$45
|
$45
|
$45
|
$45
|
$45
|
$245
|
COMMITMENTS
|
(Dollars
in millions)
|
Payments
Due For
|
|||||||||||
Period
|
Notes
and Debentures
|
Credit
Facility Borrowings and Other
|
Interest
Payable
|
Purchase
Obligations
|
Operating
Leases
|
Total
|
||||||
2008
|
$
|
72
|
$
|
--
|
$
|
98
|
$
|
508
|
$
|
32
|
$
|
710
|
2009
|
--
|
14
|
96
|
460
|
26
|
596
|
||||||
2010
|
--
|
--
|
96
|
420
|
22
|
538
|
||||||
2011
|
2
|
--
|
96
|
253
|
20
|
371
|
||||||
2012
|
148
|
188
|
84
|
246
|
12
|
678
|
||||||
2013
and beyond
|
1,183
|
--
|
945
|
403
|
65
|
2,596
|
||||||
Total
|
$
|
1,405
|
$
|
202
|
$
|
1,415
|
$
|
2,290
|
$
|
177
|
$
|
5,489
|
ENVIRONMENTAL
MATTERS
|
(Dollars
in millions)
|
December
31, 2007
|
December
31, 2006
|
||
Beginning
environmental liability
|
$
|
47
|
$
|
51
|
Liabilities
incurred in current period
|
1
|
7
|
||
Liabilities
settled in current period
|
(6)
|
(14)
|
||
Accretion
expense
|
2
|
2
|
||
Revisions
to estimated cash flow
|
(2)
|
1
|
||
Ending
environmental liability
|
$
|
42
|
$
|
47
|
LEGAL
MATTERS
|
STOCKHOLDERS'
EQUITY
|
(Dollars
in millions)
|
Common
Stock
at
Par
Value
$
|
Paid-in
Capital
$
|
Retained
Earnings
$
|
Accumulated
Other Comprehensive
Income
(Loss)
$
|
Treasury
Stock
at
Cost
$
|
Total
Stockholders’
Equity
$
|
Balance
at January 1, 2005
|
1
|
210
|
1,509
|
(103)
|
(433)
|
1,184
|
Net
Earnings
|
--
|
--
|
557
|
--
|
--
|
557
|
Cash
Dividends(1)
|
--
|
--
|
(143)
|
--
|
--
|
(143)
|
Other
Comprehensive Income
|
--
|
--
|
--
|
(97)
|
--
|
(97)
|
Stock
Option Exercises and Other Items
(2)
|
--
|
110
|
--
|
--
|
1
|
111
|
Balance
at December 31, 2005
|
1
|
320
|
1,923
|
(200)
|
(432)
|
1,612
|
Net
Earnings
|
--
|
--
|
409
|
--
|
--
|
409
|
Cash
Dividends(1)
|
--
|
--
|
(146)
|
--
|
--
|
(146)
|
Other
Comprehensive Income
|
--
|
--
|
--
|
107
|
--
|
107
|
Effect
of FAS 158 adoption
|
--
|
--
|
--
|
(81)
|
--
|
(81)
|
Stock
Option Exercises and Other Items (2)(3)
|
--
|
128
|
--
|
--
|
--
|
128
|
Balance
at December 31, 2006
|
1
|
448
|
2,186
|
(174)
|
(432)
|
2,029
|
Net
Earnings
|
--
|
--
|
300
|
--
|
--
|
300
|
Effect
of FIN 48 Adoption
|
--
|
--
|
8
|
--
|
--
|
8
|
Cash
Dividends Declared (1)
|
--
|
--
|
(145)
|
--
|
--
|
(145)
|
Other
Comprehensive Income
|
--
|
--
|
--
|
146
|
--
|
146
|
Stock
Option Exercises and Other Items (2)(3)
|
--
|
125
|
--
|
--
|
1
|
126
|
Stock
Repurchases
|
--
|
--
|
--
|
--
|
(382)
|
(382)
|
Balance
at December 31, 2007
|
1
|
573
|
2,349
|
(28)
|
(813)
|
2,082
|
|
(1) Includes
cash dividends paid and dividends declared, but unpaid. Also,
includes the redemption of the outstanding preferred stock purchase
rights.
|
|
(2) The
tax benefits relating to the difference between the amounts deductible for
federal income taxes over the amounts charged to income for book value
purposes have been credited to paid-in
capital.
|
|
(3)
Includes the fair
value of equity share-based awards recognized under SFAS No.
123(R).
|
Shares
of common stock issued (1)
|
2007
|
2006
|
2005
|
|||
Balance
at beginning of year
|
91,579,441
|
89,566,115
|
87,257,499
|
|||
Issued
for employee compensation and benefit plans
|
2,050,851
|
2,013,326
|
2,308,616
|
|||
Balance
at end of year
|
93,630,292
|
91,579,441
|
89,566,115
|
|||
(1)
Includes shares held in treasury.
|
(Dollars
in millions)
|
Cumulative
Translation Adjustment
$
|
Unfunded
Additional
Minimum
Pension
Liability
$
|
Unrecognized
Loss
and
Prior
Service
Cost,
net of
taxes
$
|
Unrealized
Gains
(Losses)
on
Cash Flow
Hedges
$
|
Unrealized
Losses
on Investments
$
|
Accumulated
Other
Comprehensive
Income
(Loss)
$
|
Balance
at December 31, 2005
|
61
|
(255)
|
--
|
(5)
|
(1)
|
(200)
|
Period
change
|
60
|
48
|
--
|
(1)
|
--
|
107
|
Pre-SFAS
No. 158 balance at December 31, 2006
|
121
|
(207)
|
--
|
(6)
|
(1)
|
(93)
|
Adjustments
to apply SFAS No. 158
|
--
|
207
|
(288)
|
--
|
--
|
(81)
|
Balance
at December 31, 2006
|
121
|
--
|
(288)
|
(6)
|
(1)
|
(174)
|
Period
change
|
36
|
--
|
106
|
3
|
1
|
146
|
Balance
at December 31, 2007
|
157
|
--
|
(182)
|
(3)
|
--
|
(28)
|
SHARE-BASED
COMPENSATION PLANS AND AWARDS
|
Assumptions
|
2007
|
2006
|
2005
|
Expected
volatility rate
|
20.80%
|
21.40%
|
22.90%
|
Expected
dividend yield
|
2.92%
|
3.24%
|
3.29%
|
Average
risk-free interest rate
|
4.24%
|
4.62%
|
4.48%
|
Expected
forfeiture rate
|
0.75%
|
0.75%
|
Actual
|
Expected
term years
|
4.40
|
4.40
|
5.00
|
2007
|
2006
|
2005
|
|||||||||
Options
|
Weighted-Average
Exercise Price
|
Options
|
Weighted-Average
Exercise Price
|
Options
|
Weighted-Average
Exercise Price
|
||||||
Outstanding
at beginning of year
|
5,866,900
|
$
|
52
|
6,616,800
|
$
|
48
|
8,155,100
|
$
|
47
|
||
Granted
|
643,000
|
65
|
1,481,300
|
61
|
1,275,700
|
54
|
|||||
Exercised
|
(2,010,100)
|
50
|
(2,001,800)
|
45
|
(2,342,600)
|
43
|
|||||
Cancelled,
forfeited or expired
|
(18,500)
|
59
|
(229,400)
|
56
|
(471,400)
|
64
|
|||||
Outstanding
at end of year
|
4,481,300
|
$
|
55
|
5,866,900
|
$
|
52
|
6,616,800
|
$
|
48
|
||
Options
exercisable at year-end
|
2,686,800
|
3,385,100
|
4,688,000
|
||||||||
Available
for grant at end of year
|
3,379,200
|
1,244,900
|
2,954,500
|
||||||||
Options
Outstanding
|
Options
Exercisable
|
|||||||||
Range
of Exercise Prices
|
Number Outstanding
at 12/31/07
|
Weighted-Average
Remaining Contractual Life (Years)
|
Weighted-Average
Exercise Price
|
Number
Exercisable at 12/31/07
|
Weighted-Average
Exercise Price
|
|||||
$30-45
|
380,900
|
4.8
|
$
|
37
|
380,600
|
$
|
37
|
|||
$46-52
|
897,800
|
4.6
|
48
|
895,600
|
48
|
|||||
$53-59
|
1,274,600
|
7.5
|
54
|
764,600
|
54
|
|||||
$60-64
|
1,351,700
|
8.6
|
61
|
507,600
|
61
|
|||||
$65-66
|
576,300
|
8.4
|
66
|
138,400
|
66
|
|||||
4,481,300
|
7.1
|
$
|
55
|
2,686,800
|
$
|
52
|
Nonvested
Options
|
Number
of Options
|
Weighted-Average
Grant Date Fair Value
|
|
Nonvested
at January 1, 2007
|
2,481,800
|
$
|
10.39
|
Granted
|
643,000
|
|
11.12
|
Vested
|
(1,320,900)
|
|
10.18
|
Forfeited
|
(9,400)
|
|
10.48
|
Nonvested
Options at December 31, 2007
|
1,794,500
|
$
|
10.87
|
DIVESTITURES
|
ASSET
IMPAIRMENTS AND RESTRUCTURING CHARGES,
NET
|
(Dollars
in millions)
|
2007
|
2006
|
2005
|
CASPI:
|
|||
Fixed
asset impairments
|
$--
|
$6
|
$--
|
Severance
charges
|
(1)
|
4
|
--
|
Site
closure and restructuring costs
|
--
|
3
|
4
|
Fibers:
|
|||
Severance
charges
|
--
|
2
|
--
|
PCI:
|
|||
Fixed
asset impairments
|
--
|
10
|
8
|
Severance
charges
|
(1)
|
6
|
3
|
Site
closure and restructuring costs
|
--
|
4
|
--
|
Performance
Polymers:
|
|||
Fixed
asset impairments
|
118
|
30
|
--
|
Severance
charges
|
(5)
|
16
|
--
|
Specialty
Plastics (“SP”):
|
|||
Fixed
asset impairments
|
2
|
12
|
--
|
Severance
charges
|
(2)
|
4
|
--
|
Site
closure and restructuring costs
|
1
|
--
|
--
|
Other:
|
|||
Fixed
asset impairments
|
--
|
3
|
1
|
Intangible
asset impairments
|
2
|
1
|
3
|
Site
closure and restructuring costs
|
(2)
|
--
|
14
|
Total
Eastman Chemical Company
|
|||
Fixed
asset impairments
|
$
120
|
$ 61
|
$ 9
|
Intangible
asset impairments
|
2
|
1
|
3
|
Severance
charges
|
(9)
|
32
|
3
|
Site
closure and restructuring costs
|
(1)
|
7
|
18
|
Total
Eastman Chemical Company
|
$
112
|
$
101
|
$ 33
|
(Dollars
in millions)
|
Balance
at
January
1, 2005
|
Provision/
Adjustments
|
Non-cash
Reductions
|
Cash
Reductions
|
Balance
at
December
31, 2005
|
|||||
Noncash
charges
|
$
|
--
|
$
|
12
|
$
|
(12)
|
$
|
--
|
$
|
--
|
Severance
costs
|
26
|
3
|
--
|
(26)
|
3
|
|||||
Site
closure and restructuring costs
|
9
|
18
|
(1)
|
(19)
|
7
|
|||||
Total
|
$
|
35
|
$
|
33
|
$
|
(13)
|
$
|
(45)
|
$
|
10
|
Balance
at
January
1, 2006
|
Provision/
Adjustments
|
Non-cash
Reductions
|
Cash
Reductions
|
Balance
at
December
31, 2006
|
||||||
Noncash
charges
|
$
|
--
|
$
|
62
|
$
|
(62)
|
$
|
--
|
$
|
--
|
Severance
costs
|
3
|
32
|
--
|
(1)
|
34
|
|||||
Site
closure and restructuring costs
|
7
|
7
|
--
|
--
|
14
|
|||||
Total
|
$
|
10
|
$
|
101
|
$
|
(62)
|
$
|
(1)
|
$
|
48
|
Balance
at
January
1, 2007
|
Provision/
Adjustments
|
Non-cash
Reductions
|
Cash
Reductions
|
Balance
at
December
31, 2007
|
||||||
Noncash
charges
|
$
|
--
|
$
|
122
|
$
|
(122)
|
$
|
--
|
$
|
--
|
Severance
costs
|
34
|
(9)
|
--
|
(18)
|
7
|
|||||
Site
closure and restructuring costs
|
14
|
(1)
|
--
|
(2)
|
11
|
|||||
Total
|
$
|
48
|
$
|
112
|
$
|
(122)
|
$
|
(20)
|
$
|
18
|
OTHER
OPERATING INCOME, NET
|
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Other
operating income, net
|
$
|
--
|
$
|
(68)
|
$
|
(2)
|
OTHER
(INCOME) CHARGES, NET
|
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Other
income
|
$
|
(33)
|
$
|
(25)
|
$
|
(8)
|
Other
charges
|
5
|
8
|
12
|
|||
Other
(income) charges, net
|
$
|
(28)
|
$
|
(17)
|
$
|
4
|
INCOME
TAXES
|
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Earnings
(loss) from continuing operations before income taxes
|
||||||
United
States
|
$
|
489
|
$
|
601
|
$
|
697
|
Outside
the United States
|
(19)
|
(7)
|
66
|
|||
Total
|
$
|
470
|
$
|
594
|
$
|
763
|
Provision
(benefit) for income taxes on earnings from continuing
operations
|
||||||
United
States
|
||||||
Current
|
$
|
173
|
$
|
135
|
$
|
80
|
Deferred
|
(24)
|
22
|
112
|
|||
Outside
the United States
|
||||||
Current
|
(30)
|
6
|
22
|
|||
Deferred
|
21
|
(14)
|
(7)
|
|||
State
and other
|
||||||
Current
|
10
|
17
|
6
|
|||
Deferred
|
(1)
|
1
|
9
|
|||
Total
|
$
|
149
|
$
|
167
|
$
|
222
|
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Unrecognized
loss and prior service cost
|
$
|
56
|
$
|
(9)
|
$
|
4
|
Cumulative
translation adjustment
|
5
|
2
|
--
|
|||
Unrealized
gains (losses) on cash flow hedges
|
3
|
(1)
|
(1)
|
|||
Total
|
$
|
64
|
$
|
(8)
|
$
|
3
|
2007
|
2006
|
2005
|
||||
Continuing
operations
|
$
|
149
|
$
|
167
|
$
|
222
|
Discontinued
operations
|
(3)
|
(1)
|
4
|
|||
Other
comprehensive income
|
64
|
(8)
|
3
|
|||
Total
|
$
|
210
|
$
|
158
|
$
|
229
|
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Amount
computed using the statutory rate
|
$
|
165
|
$
|
208
|
$
|
267
|
State
income taxes, net
|
8
|
12
|
5
|
|||
Foreign
rate variance
|
(3)
|
(2)
|
--
|
|||
Extraterritorial
income exclusion
|
--
|
(9)
|
(12)
|
|||
Domestic
manufacturing deduction
|
(11)
|
(4)
|
(5)
|
|||
ESOP
dividend payout
|
(1)
|
(2)
|
(2)
|
|||
Capital
loss benefits
|
(3)
|
(25)
|
(13)
|
|||
Change
in reserves for tax contingencies
|
(2)
|
(3)
|
(14)
|
|||
Net
operating loss benefits
|
--
|
(11)
|
--
|
|||
Donation
of intangibles
|
--
|
--
|
(12)
|
|||
Other
|
(4)
|
3
|
8
|
|||
Provision
(benefit) for income taxes
|
$
|
149
|
$
|
167
|
$
|
222
|
December
31,
|
||||
(Dollars
in millions)
|
2007
|
2006
|
||
Deferred
tax assets
|
||||
Post-employment
obligations
|
$
|
343
|
$
|
416
|
Net
operating loss carry forwards
|
130
|
115
|
||
Capital
loss carry forwards
|
42
|
47
|
||
Other
|
42
|
53
|
||
Total
deferred tax assets
|
557
|
631
|
||
Less
valuation allowance
|
(146)
|
(130)
|
||
Deferred
tax assets less valuation allowance
|
$
|
411
|
$
|
501
|
Deferred
tax liabilities
|
||||
Depreciation
|
$
|
(629)
|
$
|
(639)
|
Inventory
reserves
|
(42)
|
(50)
|
||
Total
deferred tax liabilities
|
$
|
(671)
|
$
|
(689)
|
Net
deferred tax liabilities
|
$
|
(260)
|
$
|
(188)
|
As
recorded in the Consolidated Statements of Financial
Position:
|
||||
Other
current assets
|
$
|
5
|
$
|
11
|
Other
noncurrent assets
|
45
|
83
|
||
Payables
and other current liabilities
|
(10)
|
(13)
|
||
Deferred
income tax liabilities
|
(300)
|
(269)
|
||
Net
deferred tax liabilities
|
$
|
(260)
|
$
|
(188)
|
December
31,
|
||||
(Dollars
in millions)
|
2007
|
2006
|
||
Miscellaneous
receivables
|
$
|
20
|
$
|
--
|
Payables
and other current liabilities
|
6
|
25
|
||
Other
long-term liabilities
|
24
|
20
|
||
Total
income taxes payable
|
$
|
30
|
$
|
45
|
(Dollars
in millions)
|
||
Balance
at January 1, 2007
|
$
|
28
|
Additions
based on tax positions related to current year
|
1
|
|
Reductions
for tax positions of prior years
|
(3)
|
|
Settlements
|
--
|
|
Lapse
of statute of limitations
|
(2)
|
|
Balance
at December 31, 2007
|
$
|
24
|
SUPPLEMENTAL
CASH FLOW INFORMATION
|
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Cash
paid for interest and income taxes is as follows:
|
||||||
Interest,
net of amounts capitalized
|
$
|
108
|
$
|
105
|
$
|
126
|
Income
taxes paid
|
173
|
157
|
138
|
SEGMENT
INFORMATION
|
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Sales
by Segment
|
||||||
CASPI
|
$
|
1,451
|
$
|
1,421
|
$
|
1,299
|
Fibers
|
999
|
910
|
869
|
|||
PCI
|
2,095
|
1,659
|
1,560
|
|||
Performance
Polymers
|
1,413
|
1,971
|
1,987
|
|||
SP
|
872
|
818
|
718
|
|||
Total
Sales by Segment
|
6,830
|
6,779
|
6,433
|
|||
Other
|
--
|
--
|
27
|
|||
Total
Sales
|
$
|
6,830
|
$
|
6,779
|
$
|
6,460
|
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Operating
Earnings (Loss)
|
||||||
CASPI
(1)
|
$
|
235
|
$
|
229
|
$
|
228
|
Fibers
(2)
|
238
|
226
|
216
|
|||
PCI
(3)
|
220
|
132
|
143
|
|||
Performance
Polymers (4)
|
(207)
|
68
|
159
|
|||
SP
(5)
|
65
|
46
|
64
|
|||
Total
Operating Earnings by Segment
|
551
|
701
|
810
|
|||
Other
(6)
|
(47)
|
(47)
|
(70)
|
|||
Total
Operating Earnings
|
$
|
504
|
$
|
654
|
$
|
740
|
(1)
|
CASPI
includes $(1) million, $13 million, and $4 million in 2007, 2006, and
2005, respectively, in asset impairments and restructuring charges (gains)
for previously closed manufacturing facilities and severance costs of a
voluntary reduction in force.
|
(2)
|
Fibers
includes $2 million in 2006 in asset impairments and restructuring charges
related to severance costs.
|
(3)
|
PCI
includes $(1) million, $20 million, and $11 million in 2007, 2006, and
2005, respectively, in asset impairments and restructuring charges (gains)
related to the divestiture of the Batesville, Arkansas facility,
manufacturing facilities outside the U.S. and severance charges, $19
million and $2 million in 2007 and 2006, respectively, in accelerated
depreciation related to crackers at the Company's Longview, Texas
facility, and other operating charges of $7 million related to the
divestiture of the Batesville, Arkansas
facility.
|
(4)
|
Performance
Polymers includes $113 million and $46 million in 2007 and 2006,
respectively, in asset impairments and restructuring charges related to
the PET divestitures in Mexico and Argentina, the shutdown of a research
and development pilot plant in Kingsport, Tennessee, discontinued
production of CHDM modified polymers in San Roque, Spain and severance
costs related to a reduction in force in the U.S. and Spain, $29 million
and $7 million in 2007 and 2006, respectively, of accelerated depreciation
related to assets in Columbia, South Carolina and other operating income
of $75 million in 2006 from the divestiture of the PE businesses and
related assets.
|
(5)
|
SP
includes $1 million and $16 million in 2007 and 2006, respectively, in
asset impairments and restructuring charges related to the discontinued
production of CHDM in Spain, a previously closed manufacturing facility
and severance costs, and $1 million in both 2007 and 2006 of accelerated
depreciation related to assets in Columbia, South
Carolina.
|
(6)
|
Other
includes $4 million and $18 million in 2006 and 2005, respectively
primarily for the shutdown of Cendian's business
activities.
|
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Assets
by Segment (1)
|
||||||
CASPI
|
$
|
1,114
|
$
|
1,078
|
$
|
1,009
|
Fibers
|
692
|
651
|
678
|
|||
PCI
|
1,062
|
926
|
872
|
|||
Performance
Polymers (2)
|
727
|
1,480
|
1,575
|
|||
SP
|
622
|
599
|
574
|
|||
Total
Assets by Segment
|
4,217
|
4,734
|
4,708
|
|||
Corporate
Assets
|
1,417
|
1,398
|
1,029
|
|||
Assets
Held for Sale (2)(3)
|
375
|
--
|
--
|
|||
Total
Assets
|
$
|
6,009
|
$
|
6,132
|
$
|
5,737
|
(1)
|
Assets
managed by the Chief Operating Decision Maker include accounts receivable,
inventory, fixed assets, and
goodwill.
|
(2)
|
The
Performance Polymers assets have decreased as a result of asset
impairments, divestitures in Spain and Latin America, and classification
of European assets as assets held for sale as of December 31,
2007.
|
(3)
|
For
more information regarding assets held for sale, see Note 2, "Discontinued
Operations and Assets Held for
Sale".
|
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Depreciation
Expense by Segment (1)
|
||||||
CASPI
|
$
|
53
|
$
|
54
|
$
|
55
|
Fibers
|
57
|
41
|
35
|
|||
PCI
|
70
|
59
|
76
|
|||
Performance
Polymers
|
81
|
93
|
74
|
|||
SP
|
50
|
47
|
47
|
|||
Total
Depreciation Expense by Segment
|
311
|
294
|
287
|
|||
Other
|
2
|
--
|
--
|
|||
Total
Depreciation Expense
|
$
|
313
|
$
|
294
|
$
|
287
|
(1)
|
In
the fourth quarter 2006, the Company made strategic decisions relating to
the scheduled shutdown of cracking units in Longview, Texas and a planned
shutdown of higher cost PET assets in Columbia, South
Carolina. In 2007, accelerated depreciation costs resulting
from these decisions were $19 million, $29 million, and $1 million in PCI,
Performance Polymers, and SP segments, respectively. In 2006,
accelerated depreciation costs were $2 million, $7 million, and $1 million
in PCI, Performance Polymers, and SP segments,
respectively.
|
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Capital
Expenditures by Segment
|
||||||
CASPI
|
$
|
73
|
$
|
60
|
$
|
46
|
Fibers
|
87
|
44
|
28
|
|||
PCI
|
104
|
66
|
63
|
|||
Performance
Polymers
|
126
|
125
|
137
|
|||
SP
|
111
|
94
|
67
|
|||
Total
Capital Expenditures by Segment
|
501
|
389
|
341
|
|||
Other
|
17
|
--
|
2
|
|||
Total
Capital Expenditures
|
$
|
518
|
$
|
389
|
$
|
343
|
(Dollars
in millions)
|
2007
|
2006
|
2005
|
|||
Geographic
Information
|
||||||
Sales
|
||||||
United
States
|
$
|
3,959
|
$
|
4,039
|
$
|
3,886
|
All
foreign countries
|
2,871
|
2,740
|
2,574
|
|||
Total
|
$
|
6,830
|
$
|
6,779
|
$
|
6,460
|
Long-Lived
Assets, Net
|
||||||
United
States
|
$
|
2,564
|
$
|
2,407
|
$
|
2,508
|
All
foreign countries
|
518
|
662
|
654
|
|||
Total
|
$
|
3,082
|
$
|
3,069
|
$
|
3,162
|
QUARTERLY
SALES AND EARNINGS DATA - UNAUDITED
|
(Dollars
in millions, except per share amounts)
|
First
Quarter
|
Second
Quarter
|
Third
Quarter
|
Fourth
Quarter(2)
|
||||
2007
|
||||||||
Sales
|
$
|
1,637
|
$
|
1,764
|
$
|
1,692
|
$
|
1,737
|
Gross
profit
|
286
|
309
|
307
|
290
|
||||
Asset
impairment and restructuring charges
|
--
|
2
|
114
|
(4)
|
||||
Earnings
from continuing operations
|
93
|
102
|
25
|
101
|
||||
Earnings
(loss) from discontinued operations, net of tax
|
(3)
|
1
|
(5)
|
(3)
|
||||
Gain
(loss) from disposal of discontinued operations, net of
tax
|
(13)
|
2
|
--
|
--
|
||||
Net
earnings
|
77
|
105
|
20
|
98
|
||||
Earnings
from continuing operations per share (1)
|
||||||||
Basic
|
$
|
1.11
|
$
|
1.21
|
$
|
0.30
|
$
|
1.26
|
Diluted
|
$
|
1.10
|
$
|
1.19
|
$
|
0.30
|
$
|
1.25
|
Earnings
(loss) from discontinued operations per share (1)
|
||||||||
Basic
|
$
|
(0.20)
|
$
|
0.03
|
$
|
(0.06)
|
$
|
(0.04)
|
Diluted
|
$
|
(0.20)
|
$
|
0.03
|
$
|
(0.06)
|
$
|
(0.04)
|
Net
earnings per share (1)
|
||||||||
Basic
|
$
|
0.92
|
$
|
1.24
|
$
|
0.24
|
$
|
1.22
|
Diluted
|
$
|
0.91
|
$
|
1.22
|
$
|
0.24
|
$
|
1.21
|
|
(1) Each
quarter is calculated as a discrete period; the sum of the four quarters
may not equal the calculated full-year
amount.
|
|
(2) In
fourth quarter 2007, the Company completed the sale of its Argentina and
Mexico manufacturing sites and related
businesses.
|
(Dollars
in millions, except per share amounts)
|
First
Quarter
|
Second
Quarter
|
Third
Quarter
|
Fourth
Quarter(2)
|
||||
2006
|
||||||||
Sales
|
$
|
1,655
|
$
|
1,751
|
$
|
1,779
|
$
|
1,594
|
Gross
profit
|
329
|
341
|
310
|
285
|
||||
Asset
impairment and restructuring charges
|
7
|
3
|
13
|
78
|
||||
Earnings
from continuing operations
|
110
|
116
|
94
|
107
|
||||
Earnings
(loss) from discontinued operations, net of tax
|
(5)
|
(2)
|
1
|
(12)
|
||||
Net
earnings
|
105
|
114
|
95
|
95
|
||||
Earnings
from continuing operations per share (1)
|
||||||||
Basic
|
$
|
1.34
|
$
|
1.41
|
$
|
1.15
|
$
|
1.28
|
Diluted
|
$
|
1.33
|
$
|
1.39
|
$
|
1.14
|
$
|
1.26
|
Earnings
(loss) from discontinued operations per share (1)
|
||||||||
Basic
|
$
|
(0.06)
|
$
|
(0.02)
|
$
|
0.01
|
$
|
(0.14)
|
Diluted
|
$
|
(0.06)
|
$
|
(0.02)
|
$
|
0.01
|
$
|
(0.14)
|
Net
earnings per share (1)
|
||||||||
Basic
|
$
|
1.28
|
$
|
1.39
|
$
|
1.16
|
$
|
1.14
|
Diluted
|
$
|
1.27
|
$
|
1.37
|
$
|
1.15
|
$
|
1.12
|
|
(1) Each
quarter is calculated as a discrete period; the sum of the four quarters
may not equal the calculated full-year
amount.
|
|
(2) In
fourth quarter 2006, the Company completed the sale of its Batesville,
Arkansas manufacturing site and related businesses and its PE and
EpoleneTM
polymer businesses, related assets and ethylene pipeline located at
Longview, Texas.
|
RECENTLY
ISSUED ACCOUNTING STANDARDS
|
RESERVE
ROLLFORWARDS
|
Additions
|
||||||||||
(Dollars
in millions)
|
Balance
at
January
1, 2005
|
Charged
to Cost and Expense
|
Charged
to Other Accounts
|
Deductions
|
Balance
at
December
31, 2005
|
|||||
Reserve
for:
|
||||||||||
Doubtful
accounts and returns
|
$
|
15
|
$
|
9
|
$
|
--
|
$
|
4
|
$
|
20
|
LIFO
Inventory
|
355
|
92
|
--
|
--
|
447
|
|||||
Environmental
contingencies
|
56
|
4
|
--
|
9
|
51
|
|||||
Deferred
tax valuation allowance
|
221
|
(21)
|
(3)
|
--
|
197
|
|||||
$
|
647
|
$
|
84
|
$
|
(3)
|
$
|
13
|
$
|
715
|
|
Balance
at
January
1, 2006
|
Charged
to Cost and Expense
|
Charged
to Other Accounts
|
Deductions
|
Balance
at
December
31, 2006
|
||||||
Reserve
for:
|
||||||||||
Doubtful
accounts and returns
|
$
|
20
|
$
|
(3)
|
$
|
--
|
$
|
2
|
$
|
15
|
LIFO
Inventory
|
447
|
17
|
--
|
--
|
464
|
|||||
Environmental
contingencies
|
51
|
10
|
--
|
14
|
47
|
|||||
Deferred
tax valuation allowance
|
197
|
(67)
|
--
|
--
|
130
|
|||||
$
|
715
|
$
|
(43)
|
$
|
--
|
$
|
16
|
$
|
656
|
|
Balance
at
January
1, 2007
|
Charged
to Cost and Expense
|
Charged
to Other Accounts
|
Deductions
|
Balance
at
December
31, 2007
|
||||||
Reserve
for:
|
||||||||||
Doubtful
accounts and returns
|
$
|
15
|
$
|
(1)
|
$
|
--
|
$
|
8
|
$
|
6
|
LIFO
Inventory
|
464
|
46
|
--
|
--
|
510
|
|||||
Environmental
contingencies
|
47
|
3
|
--
|
8
|
42
|
|||||
Deferred
tax valuation allowance
|
130
|
8
|
8
|
--
|
146
|
|||||
$
|
656
|
$
|
56
|
$
|
8
|
$
|
16
|
$
|
704
|
|
CONTROLS
AND PROCEDURES
|
|
Pertain
to the maintenance of records that, in reasonable detail, accurately and
fairly reflect transactions and dispositions of assets of the
Company;
|
|
Provide
reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with U.S. generally
accepted accounting principles, and that receipts and expenditures of the
Company are being made only in accordance with authorizations of
management and the directors of the Company;
and
|
|
Provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of the Company’s assets that
could have a material effect on the Company’s financial
statements.
|
OTHER
INFORMATION
|
DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE
|
Plan
Category
|
Number
of Securities to be Issued upon Exercise of Outstanding
Options
(a)
|
Weighted-Average
Exercise Price of Outstanding Options
(b)
|
Number
of Securities Remaining Available for Future Issuance Under Equity
Compensation Plans (Excluding Securities reflected in Column
(a))
(c)
|
||||
Equity
compensation plans approved by stockholders
|
4,481,300
|
(1)
|
$55
|
3,379,200
|
(2)
|
||
Equity
compensation plans not approved by stockholders
|
--
|
--
|
--
|
||||
TOTAL
|
4,481,300
|
$55
|
3,379,200
|
|
(1)
Represents shares of common stock issuable upon exercise of options
granted under Eastman Chemical Company’s 1997, 2002, and 2007 Omnibus
Long-Term Compensation Plans; the 1999 and 2002 Director Long-Term
Compensation Plans; the 1996 Non-Employee Director Stock Option Plan and
2007 Director Long Term Compensation
Subplan.
|
|
(2)
Shares of common stock available for future awards under the
Company’s 2007 Omnibus Long-Term Compensation Plan including the 2007
Director Long-Term Compensation Subplan, a component of the 2007 Omnibus
Long-Term Compensation Plan.
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
|
EXHIBITS
AND FINANCIAL STATEMENT SCHEDULES
|
Page
|
||||
(a)
|
1.
|
Consolidated
Financial Statements:
|
||
77
|
||||
78
|
||||
80
|
||||
81
|
||||
82
|
||||
83
|
||||
2.
|
136
|
|||
(b)
|
||||
Eastman
Chemical Company
|
||
By:
|
\s\ J. Brian Ferguson | |
J.
Brian Ferguson
|
||
Chairman
of the Board and Chief Executive Officer
|
||
Date:
|
February
28, 2008
|
SIGNATURE
|
TITLE
|
DATE
|
||
PRINCIPAL
EXECUTIVE OFFICER:
|
||||
\s\ J. Brian Ferguson |
Chairman
of the Board of Directors
|
February
28, 2008
|
||
J.
Brian Ferguson
|
and
Chief Executive Officer
|
|||
PRINCIPAL
FINANCIAL OFFICER:
|
||||
\s\ Richard A. Lorraine |
Senior
Vice President and
|
February
28, 2008
|
||
Richard
A. Lorraine
|
Chief
Financial Officer
|
|||
PRINCIPAL
ACCOUNTING OFFICER:
|
||||
\s\ Curtis E. Espeland |
Vice
President, Finance and
|
February
28, 2008
|
||
Curtis
E. Espeland
|
Chief
Accounting Officer
|
|||
SIGNATURE
|
TITLE
|
DATE
|
||
DIRECTORS:
|
||||
/s/ Gary E. Anderon |
Director
|
February
28, 2008
|
||
Gary
E. Anderson
|
||||
/s/ Michael P. Connors |
Director
|
February
28, 2008
|
||
Michael
P. Connors
|
||||
/s/ Stephen R. Demeritt |
Director
|
February
28, 2008
|
||
Stephen
R. Demeritt
|
||||
/s/ Donald W. Griffin |
Director
|
February
28, 2008
|
||
Donald
W. Griffin
|
||||
/s/ Robert M. Hernandez |
Director
|
February
28, 2008
|
||
Robert
M. Hernandez
|
||||
/s/ Renee J. Hornbaker |
Director
|
February
28, 2008
|
||
Renẻe
J. Hornbaker
|
||||
/s/ Lewis M. Kling |
Director
|
February
28, 2008
|
||
Lewis
M. Kling
|
||||
/s/ Howard L. Lance |
Director
|
February
28, 2008
|
||
Howard
L. Lance
|
||||
/s/ Thomas H. McLain |
Director
|
February
28, 2008
|
||
Thomas
H. McLain
|
||||
/s/ David W. Raisbeck |
Director
|
February
28, 2008
|
||
David
W. Raisbeck
|
||||
/s/ Peter M. Wood |
Director
|
February
28, 2008
|
||
Sequential
|
||||
Exhibit
|
Page
|
|||
Number
|
Description
|
Number
|
||
3.01
|
Amended
and Restated Certificate of Incorporation of Eastman Chemical Company, as
amended (incorporated herein by reference to Exhibit 3.01 to Eastman
Chemical Company's Quarterly Report on Form 10-Q for the quarter ended
June 30, 2001)
|
|||
3.02
|
Amended
and Restated Bylaws of Eastman Chemical Company, as
amended November 9, 2007 (incorporated herein
by referenced to Exhibit 3.02 to Eastman Chemical
Company’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2007 (the “September 30, 2007 10-Q”)
|
|||
4.01
|
Form
of Eastman Chemical Company common stock certificate as amended February
1, 2001 (incorporated herein by reference to Exhibit 4.01 to Eastman
Chemical Company’s Quarterly Report on Form 10-Q for the quarter ended
March 31, 2001)
|
|||
4.02
|
Indenture,
dated as of January 10, 1994, between Eastman Chemical Company and The
Bank of New York, as Trustee (the "Indenture") (incorporated herein by
reference to Exhibit 4(a) to Eastman Chemical Company's Current Report on
Form 8-K dated January 10, 1994 (the "8-K"))
|
|||
4.03
|
Form
of 7 1/4% Debentures due January 15, 2024 (incorporated herein by
reference to Exhibit 4(d) to the 8-K)
|
|||
4.04
|
Officers’
Certificate pursuant to Sections 201 and 301 of the Indenture
(incorporated herein by reference to Exhibit 4(a) to Eastman Chemical
Company's Current Report on Form 8-K dated June 8, 1994 (the "June
8-K"))
|
|||
4.05
|
Form
of 7 5/8% Debentures due June 15, 2024 (incorporated herein by reference
to Exhibit 4(b) to the June 8-K)
|
|||
4.06
|
Form
of 7.60% Debentures due February 1, 2027 (incorporated herein by reference
to Exhibit 4.08 to Eastman Chemical Company's Annual Report on Form 10-K
for the year ended December 31, 1996 (the "1996 10-K"))
|
|||
4.07
|
Form
of 7% Notes due April 15, 2012 (incorporated herein by reference to
Exhibit 4.09 to Eastman Chemical Company's Quarterly Report on Form 10-Q
for the quarter ended March 31, 2002)
|
|||
4.08
|
Officer's
Certificate pursuant to Sections 201 and 301 of the Indenture related to
7.60% Debentures due February 1, 2027 (incorporated herein by reference to
Exhibit 4.09 to the 1996 10-K)
|
|||
4.09
|
$200,000,000
Accounts Receivable Securitization agreement dated April 13, 1999 (amended
April 11, 2000), between the Company and Bank One, N.A., as agent.
Pursuant to Item 601(b)(4)(iii) of Regulation S-K, in lieu of filing a
copy of such agreement, the Company agrees to furnish a copy of such
agreement to the Commission upon request
|
|||
4.10
|
Amended
and Restated Credit Agreement, dated as of April 3, 2006 (the "Credit
Agreement") among Eastman Chemical Company, the Lenders named therein, and
Citigroup Global Markets , Inc. and J. P. Morgan Securities Inc.,
as joint lead arrangers (incorporated herein by reference to
Exhibit 4.11 to Eastman Chemical Company's Quarterly Report on Form 10-Q
for the quarter ended June 30, 2006)
|
EXHIBIT
INDEX
|
Sequential
|
|||
Exhibit
|
Page
|
|||
Number
|
Description
|
Number
|
||
4.11
|
Form
of 3 ¼% Notes due June 16, 2008 (incorporated herein by reference to
Exhibit 4.13 to Eastman Chemical Company’s Quarterly Report on Form 10-Q
for the quarter ended June 30, 2003)
|
|||
4.12
|
Form
of 6.30% Notes due 2018 (incorporated herein by reference to Exhibit 4.14
to Eastman Chemical Company’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2003)
|
|||
10.01*
|
1996
Non-Employee Director Stock Option Plan (incorporated herein by reference
to Exhibit 10.02 to Eastman Chemical Company's Quarterly Report on Form
10-Q for the quarter ended September 30, 1996)
|
|||
10.02*
|
Employment
Agreement between Eastman Chemical Company and James P. Rogers
(incorporated herein by reference to Exhibit 10.02 to Eastman Chemical
Company's Quarterly Report on Form 10-Q for the quarter ended September
30, 1999)
|
|||
10.03*
|
Eastman
Excess Retirement Income Plan, amended and restated effective January 1,
2008 (incorporated herein by reference to Exhibit 10.06 to the September
30, 2007 10-Q)
|
|||
10.04*
|
Form
of Executive Severance Agreements (incorporated herein by reference to
Exhibit 99.01 to Eastman Chemical Company's Current Report on Form 8-K
dated December 5, 2005)
|
|||
10.05*
|
Eastman
Unfunded Retirement Income Plan, amended and restated effective January 1,
2008 (incorporated herein by reference to Exhibit 10.07 to the September
30, 2007 10-Q)
|
|||
10.06*
|
2002
Omnibus Long-Term Compensation Plan, as amended (incorporated
herein by reference to Exhibit 10.02 to the September 30, 2007
10-Q)
|
|||
10.07*
|
2002
Director Long-Term Compensation Plan, as amended (incorporated herein by
reference to Appendix A to Eastman Chemical Company’s 2002 Annual Meeting
Proxy Statement)
|
|||
10.08*
|
Amended
and Restated Eastman Chemical Company Benefit Security Trust dated January
2, 2002 (incorporated herein by reference to Exhibit 10.04 to Eastman
Chemical Company's Quarterly Report on Form 10-Q for the quarter ended
September 30, 2002, (the "September 30, 2002 10-Q")
|
|||
10.09*
|
Amended
and Restated Warrant to Purchase Shares of Common Stock of Eastman
Chemical Company, dated January 2, 2002 (incorporated herein by reference
to Exhibit 10.02 to the September 30, 2002 10-Q)
|
|||
10.10*
|
Amended
and Restated Registration Rights Agreement, dated January 2, 2002
(incorporated herein by reference to Exhibit 10.03 to the September 30,
2002 10-Q)
|
|||
10.11*
|
Notice
of Restricted Stock Granted October 7, 2002 (incorporated herein by
reference to Exhibit 10.01 to the September 30, 2002 10-Q)
|
EXHIBIT
INDEX
|
Sequential
|
|||
Exhibit
|
Page
|
|||
Number
|
Description
|
Number
|
||
10.12*
|
Amended
and Restated Eastman Executive Deferred Compensation Plan (incorporated
herein by referenced to Exhibit 10.04 to the September 30, 2007
10-Q)
|
|||
10.13*
|
Amended
Directors' Deferred Compensation Plan (incorporated herein by reference to
Exhibit 10.05 to the September 30, 2007 10-Q)
|
|||
10.14*
|
Eastman
Unit Performance Plan as amended and restated January 1, 2004
(incorporated herein by reference to Exhibit 10.09 to Eastman Chemical
Company's Annual Report on Form 10-K for the year ended December 31, 2003
(the "2003 10-K"))
|
|||
10.15*
|
Form
of Indemnification Agreements with Directors and Executive Officers
(incorporated herein by reference to Exhibit 10.25 to the 2003
10-K)
|
|||
10.16*
|
Form
of Performance Share Awards to Executive Officers (2005 – 2007 Performance
Period) (incorporated herein by reference to Exhibit 10.02 to the
September 30, 2004 10-Q)
|
|||
10.17*
|
Form
of Performance Share Awards to Executive Officers (2006 – 2008 Performance
Period) (incorporated herein by reference to Exhibit 10.04 to Eastman
Chemical Company's Quarterly Report on Form 10-Q for the quarter ended
September 30, 2005)
|
|||
10.18*
|
Unit
Performance Plan ("UPP") performance measures and goals, specific target
objectives with respect to such performance goals, the method for
computing the amount of the UPP award allocated to the award pool if the
performance goals are attained, and the eligibility criteria for employee
participation in the UPP, for the 2007 performance year (incorporated
herein by reference to Eastman Chemical Company’s Current Report on Form
8-K dated December 7, 2006)
|
|||
10.19*
|
Employment
Agreement between Eastman Chemical Company and Mark J. Costa dated May 4,
2006 (incorporated herein by reference to Exhibit 10.01 to Eastman
Chemical Company's Quarterly Report on Form 10-Q for the quarter ended
June 30, 2006 (the "June 30, 2006 10-Q")
|
|||
10.20*
|
Notice
of Restricted Stock Awarded to Mark J. Costa on June 1, 2006 (incorporated
herein by reference to Exhibit 10.02 to the June 30, 2006
10-Q)
|
|||
10.21*
|
Notice
of Stock Option Granted to Mark J. Costa on June 1, 2006 (incorporated
herein by reference to Exhibit 10.03 to the June 30, 2006
10-Q)
|
|||
10.22*
|
Form
of Award Notice for Stock Options Granted to Executive Officers under the
2002 Omnibus Long-Term Compensation Plan (incorporated herein by reference
to Exhibit 10.01 to Eastman Chemical Company's Quarterly Report on Form
10-Q for the quarter ended September 30, 2006 )
|
|||
10.23*
|
Form
of Award Notice for Stock Options Granted to Executive Officers under the
2007 Omnibus Long-Term Compensation Plan (incorporated herein by reference
to Exhibit 10.08 to the September 30, 2007 10-Q )
|
|||
10.24*
|
Form
of Award Notice for Stock Option Granted to Mark J. Costa, Senior
Vice-President, Corporate Strategy and Marketing (incorporated herein by
reference to Exhibit 10.02 to the September 30, 2006 10-Q)
|
EXHIBIT
INDEX
|
Sequential
|
|||
Exhibit
|
Page
|
|||
Number
|
Description
|
Number
|
||
10.25*
|
Form
of Performance Share Awards to Executive Officers (2007 – 2009 Performance
Period) (incorporated herein by reference to Exhibit 10.03 to the
September 30, 2006 10-Q)
|
|||
10.26*
|
Form
of Performance Share Award to Mark J. Costa, Senior Vice-President,
Corporate Strategy and Marketing (2007-2009 Performance Period)
(incorporated herein by reference to Exhibit 10.04 to the September 30,
2006 10-Q)
|
|||
10.27*
|
Unit
Performance Plan ("UPP") performance measures and goals, specific target
objectives with respect to such performance goals, the method for
computing the amount of the UPP award allocated to the award pool if the
performance goals are attained, and the eligibility criteria for employee
participation in the UPP, for the 2007 performance year (incorporated
herein by reference to Eastman Chemical Company’s Current Report on Form
8-K dated December 7, 2006)
|
|||
10.28*
|
1997
Omnibus Long-Term Compensation Plan, as amended (incorporated
herein by reference to Exhibit 10.03 to the September 30, 2007
10-Q)
|
|||
10.29*
|
2007
Omnibus Long-Term Compensation Plan, as amended (incorporated
herein by reference to Exhibit 10.01 to the September 30, 2007
10-Q)
|
|||
10.30*
|
Forms
of Performance Share Awards to Executive Officers (2008 – 2010 Performance
Period) (incorporated herein by reference to Exhibit 10.09 to the
September 30, 2007 10-Q)
|
|||
10.31*
|
2007
Director Long-Term Compensation Subplan of the 2007 Omnibus Long-Term
Compensation Plan (incorporated herein by reference to Exhibit 10.10 to
the September 30, 2007 10-Q)
|
|||
10.32*
|
Unit
Performance Plan ("UPP") performance measures and goals, specific target
objectives with respect to such performance goals, the method for
computing the amount of the UPP award allocated to the award pool if the
performance goals are attained, and the eligibility criteria for employee
participation in the UPP, for the 2008 performance year (incorporated
herein by reference to Eastman Chemical Company’s Current Report on Form
8-K dated December 5, 2007)
|
|||
12.01
|
140
|
|||
21.01
|
141-143
|
|||
23.01
|
144
|
|||
31.01
|
145
|
|||
31.02
|
146
|
|||
32.01
|
147
|
|||
32.02
|
148
|
|||
* Management contract or
compensatory plan or arrangement filed pursuant to Item 601(b) (10) (iii)
of Regulation S-K.
|